<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosgen</journal-id>
<journal-title-group>
<journal-title>PLOS Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-7390</issn>
<issn pub-type="epub">1553-7404</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pgen.1006308</article-id>
<article-id pub-id-type="publisher-id">PGENETICS-D-16-00414</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic endocrinology</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Carbohydrate metabolism</subject><subj-group><subject>Glucose metabolism</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Animal models</subject><subj-group><subject>Mouse models</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological tissue</subject><subj-group><subject>Adipose tissue</subject><subj-group><subject>Brown adipose tissue</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological tissue</subject><subj-group><subject>Adipose tissue</subject><subj-group><subject>Brown adipose tissue</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Glucose tolerance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Molecular biology assays and analysis techniques</subject><subj-group><subject>Gene expression and vector techniques</subject><subj-group><subject>Hyperexpression techniques</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Molecular biology assays and analysis techniques</subject><subj-group><subject>Gene expression and vector techniques</subject><subj-group><subject>Hyperexpression techniques</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>MiR-155 Enhances Insulin Sensitivity by Coordinated Regulation of Multiple Genes in Mice</article-title>
<alt-title alt-title-type="running-head">MiR-155 Regulate Insulin Sensitivity in Mice</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Lin</surname>
<given-names>Xiaolin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Qin</surname>
<given-names>Yujuan</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Jia</surname>
<given-names>Junshuang</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lin</surname>
<given-names>Taoyan</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lin</surname>
<given-names>Xia</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chen</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zeng</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Han</surname>
<given-names>Yanjiang</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wu</surname>
<given-names>Lihong</given-names>
</name>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Huang</surname>
<given-names>Shun</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Meng</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Huang</surname>
<given-names>Shenhao</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Xie</surname>
<given-names>Raoying</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liang</surname>
<given-names>Liqi</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Ruiyu</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Tingting</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Shengchun</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Penghui</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Huang</surname>
<given-names>Wenhua</given-names>
</name>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Yao</surname>
<given-names>Kaitai</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Kang</given-names>
</name>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Du</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Guangdong Provincial Key Laboratory of Cancer Immunotherapy Research and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, Southern Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Endocrinology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>NanFang PET Center, Nanfang Hospital, Southern Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of Anatomy, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, School of Basic Medical Science, Southern Medical University, Guangzhou, China</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Department of General Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Institute of Comparative Medicine &amp; Laboratory Animal Center, Southern Medical University, Guangzhou, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Allison W.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of California San Francisco, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"><list-item><p><bold>Conceived and designed the experiments:</bold> DX KX XiaoL TD.</p></list-item> <list-item><p><bold>Performed the experiments:</bold> XiaoL YQ JJ TL XiaL LC HZ YH LW ShunH MW ShenH RX LL YL RL TZ JL SW PS.</p></list-item> <list-item><p><bold>Analyzed the data:</bold> DX KX XiaoL YQ.</p></list-item> <list-item><p><bold>Contributed reagents/materials/analysis tools:</bold> WH KY.</p></list-item> <list-item><p><bold>Wrote the paper:</bold> DX XiaoL KX.</p></list-item> <list-item><p><bold>General and administrative support:</bold> KY.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">yao.kaitai@hotmail.com</email> (KY); <email xlink:type="simple">xukang1995@yahoo.com</email> (KX); <email xlink:type="simple">gyeydu@163.com</email> (TD); <email xlink:type="simple">Xiao_d@hotmail.com</email> (DX)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>6</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>10</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<issue>10</issue>
<elocation-id>e1006308</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>2</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>8</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Lin et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pgen.1006308"/>
<abstract>
<p>miR-155 plays critical roles in numerous physiological and pathological processes, however, its function in the regulation of blood glucose homeostasis and insulin sensitivity and underlying mechanisms remain unknown. Here, we reveal that miR-155 levels are downregulated in serum from type 2 diabetes (T2D) patients, suggesting that miR-155 might be involved in blood glucose control and diabetes. Gain-of-function and loss-of-function studies in mice demonstrate that miR-155 has no effects on the pancreatic β-cell proliferation and function. Global transgenic overexpression of miR-155 in mice leads to hypoglycaemia, improved glucose tolerance and insulin sensitivity. Conversely, miR-155 deficiency in mice causes hyperglycemia, impaired glucose tolerance and insulin resistance. In addition, consistent with a positive regulatory role of miR-155 in glucose metabolism, miR-155 positively modulates glucose uptake in all cell types examined, while mice overexpressing miR-155 transgene show enhanced glycolysis, and insulin-stimulated AKT and IRS-1 phosphorylation in liver, adipose tissue or skeletal muscle. Furthermore, we reveal these aforementioned phenomena occur, at least partially, through miR-155-mediated repression of important negative regulators (i.e. C/EBPβ, HDAC4 and SOCS1) of insulin signaling. Taken together, these findings demonstrate, for the first time, that miR-155 is a positive regulator of insulin sensitivity with potential applications for diabetes treatment.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>In the present study, we provide evidence for the first time showing that miR-155 is a positive regulator of insulin sensitivity in mice. Here, we determine that miR-155 levels are downregulated in serum from type 2 diabetes (T2D) patients, and shows a negative correlation with HOMA-IR, suggesting that miR-155 might be involved in glucose homeostasis and insulin action. Global transgenic overexpression of miR-155 in mice leads to hypoglycaemia, improved glucose tolerance and insulin sensitivity. Conversely, miR-155 deficiency in mice causes hyperglycemia, impaired glucose tolerance and insulin resistance. In addition, consistent with a positive regulatory role of miR-155 in glucose metabolism, miR-155 positively modulates glucose uptake in all cell types examined, while mice overexpressing miR-155 transgene show enhanced glycolysis, and insulin-stimulated AKT and IRS-1 phosphorylation in liver, adipose tissue or skeletal muscle. More importantly, we reveal that these aforementioned phenomena occur, at least in part, through the miR-155-mediated coordinated repression of multiple negative regulators (i.e. C/EBPβ, HDAC4 and SOCS1) of insulin signaling.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>the National Natural Science Foundation of China</institution>
</funding-source>
<award-id>61427807</award-id>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>the National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81172587</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81372896</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81100573</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Du</surname>
<given-names>Tao</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution>the Natural Science Foundation of Guangdong Province of China</institution>
</funding-source>
<award-id>2014A030313294</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution>the Natural Science Foundation of Guangdong Province of China</institution>
</funding-source>
<award-id>2014A030313488</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Du</surname>
<given-names>Tao</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>the Natural Science Foundation of Guangdong Province of China</institution>
</funding-source>
<award-id>9151063101000015</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Jia</surname>
<given-names>Junshuang</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award008">
<funding-source>
<institution>the Natural Science Foundation of Guangdong Province of China</institution>
</funding-source>
<award-id>S2012010009212</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xu</surname>
<given-names>Kang</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award009">
<funding-source>
<institution>the Science and Technology Planning Project of Guangdong Province of China</institution>
</funding-source>
<award-id>2009B060300008</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award010">
<funding-source>
<institution>the Science and Technology Planning Project of Guangdong Province of China</institution>
</funding-source>
<award-id>2013B060300013</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award011">
<funding-source>
<institution>the China Postdoctoral Science Foundation</institution>
</funding-source>
<award-id>2015M572338</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Lin</surname>
<given-names>Xiaolin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award012">
<funding-source>
<institution>the Fundamental Research Funds for the Central Universities of China</institution>
</funding-source>
<award-id>10ykpy21</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Xu</surname>
<given-names>Kang</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award013">
<funding-source>
<institution>the Medical Scientific Research Foundation of Guangdong Province of China</institution>
</funding-source>
<award-id>A2015522</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Du</surname>
<given-names>Tao</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award014">
<funding-source>
<institution>the Introduced Major Research and Development Project Funded by Fujian Province</institution>
</funding-source>
<award-id>2012I2014</award-id>
</award-group>
<funding-statement>This work was supported by the National Natural Science Foundation of China (<ext-link ext-link-type="uri" xlink:href="http://www.nsfc.gov.cn" xlink:type="simple">http://www.nsfc.gov.cn</ext-link>) (Grant No. 81172587 and 81372896, 81672689, to DX; Grant No. 81600488, to XiaoL; Grant No. 81100573, to TD; Grant No. 81572197, to Wei Ye; Grant No. 31271042, to Jinzhong Li; Grant No. 61427807 to Huafeng Liu), the Natural Science Foundation of Guangdong Province of China (<ext-link ext-link-type="uri" xlink:href="http://pro.gdstc.gov.cn" xlink:type="simple">http://pro.gdstc.gov.cn</ext-link>) (Grant No. 2014A030313294 to DX; Grant No. 2014A030313488 to TD; Grant No. 9151063101000015, to JJ; Grant No. S2012010009212, to KX; Grant No. 2016A030313189, to Wei Ye), the Science and Technology Planning Project of Guangdong Province of China (<ext-link ext-link-type="uri" xlink:href="http://pro.gdstc.gov.cn" xlink:type="simple">http://pro.gdstc.gov.cn</ext-link>) (Grant No. 2009B060300008 and 2013B060300013, to DX; Grant No. 2015A030302024, to XiaoL; Grant No. 2015A030302014, to KX; Grant No. 2016A030303066 to TD; Grant No. 2012B061700099, to Jinzhong Li), the Science and Technology Planning Project of Guangzhou City of China (<ext-link ext-link-type="uri" xlink:href="http://apply.gzkj.gov.cn" xlink:type="simple">http://apply.gzkj.gov.cn</ext-link>) (Grant No. 2016007010036, to TD) and the China Postdoctoral Science Foundation (<ext-link ext-link-type="uri" xlink:href="http://jj.chinapostdoctor.org.cn" xlink:type="simple">http://jj.chinapostdoctor.org.cn</ext-link>)(Grant No. 2015M572338 and Grant No. 2016T90792, to XiaoL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="0"/>
<page-count count="27"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Diabetes is recognized as one of the most important health threats of our time[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref004">4</xref>]. However, the major mechanisms underlying the pathogenesis of diabetes remain unclear. microRNAs (miRNAs) are involved in glucose homeostasis, insulin sensitivity and pancreatic β-cell function, and the pathogenesis of diabetes[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref004">4</xref>]. miR-375 and miR-34a are associated with pancreatic development, and miR-375 and miR-9 are implicated in insulin secretion[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>]. miRNAs, including miR-103/miR-107, miR-143 and miR-802, have been confirmed to be negative regulators of insulin sensitivity in intact animals[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>]. However, much work remains to be done to discover miRNAs that play positive roles in regulating insulin sensitivity and glucose metabolism, which provides us a better understanding of the functions of these miRNAs in modulating blood glucose homeostasis and greatly helps us find more potential treatment targets.</p>
<p>As a multifunctional miRNA, miR-155 plays crucial roles in various physiological and pathological processes, such as haematopoietic lineage differentiation, cardiovascular diseases and cancer[<xref ref-type="bibr" rid="pgen.1006308.ref005">5</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref007">7</xref>]. Our report showed that Rm155LG/Alb-Cre transgenic mice with liver-specific miR-155 overexpression exhibited the reduced levels of hepatic and serum lipid compositions[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>]. In pilot experiment, we found that miR-155 levels in serum of type 2 diabetes (T2D) patients were lower than in healthy subjects, suggesting that miR-155 might be involved in blood glucose control and diabetes, which remains to be fully explored.</p>
<p>In the present study, we investigate the roles of miR-155 in blood glucose homeostasis, as well as the underlying mechanisms. Our findings show, for the first time, that miR-155 enhances insulin sensitivity through coordinated regulation of multiple genes in mice, including important negative regulators (i.e. C/EBPβ, HDAC4 and SOCS1) of insulin signaling.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Dysregulated miR-155 levels in serum from T2D patients</title>
<p>We evaluated the levels of miRNAs in serum of T2D patients. miR-146a levels were decreased in serum[<xref ref-type="bibr" rid="pgen.1006308.ref009">9</xref>] and peripheral blood mononuclear cells (PBMCs)[<xref ref-type="bibr" rid="pgen.1006308.ref010">10</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref011">11</xref>] from T2D patients, while hepatic overexpression of miR-107 induced hyperglycaemia and insulin resistance in mice[<xref ref-type="bibr" rid="pgen.1006308.ref012">12</xref>]. Thus, miR-146a and miR-107 are chosen as references to evaluate the serum miR-155 levels in T2D patients. qRT-PCR analysis revealed a higher levels of miR-107 (<xref ref-type="fig" rid="pgen.1006308.g001">Fig 1A</xref>) and a lower levels of miR-155 and miR-146a (<xref ref-type="fig" rid="pgen.1006308.g001">Fig 1B</xref>) in serum from patients with type 2 diabetes mellitus (T2DM). Moreover, miR-155 levels showed negative correlation with HOMA-IR (R2 = 0.1191, <italic>P</italic> = 0.0069, <xref ref-type="fig" rid="pgen.1006308.g001">Fig 1C</xref>) and no statistically significant correlation with HOMA-β (R2 = 0.0346, <italic>P</italic> = 0.1548, <xref ref-type="fig" rid="pgen.1006308.g001">Fig 1D</xref>). Together, our observations strongly support that miR-155 might be involved in glucose homeostasis and insulin action.</p>
<fig id="pgen.1006308.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Dysregulated miR-155 levels in serum from T2D patients.</title>
<p><bold>(A-B)</bold> Basal levels of miR-107(A), miR-155 (B) and miR-146a (B) in healthy subjects (HS) (n = 30) and T2D patients (n = 30) detected by qRT-PCR. Values are statistically significant at **<italic>P</italic>&lt;0.01. <bold>(C-D)</bold> miR155 levels and homeostasis model indicators (HOMA-IR and HOMA-β). HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec004">
<title>Global overexpression of miR-155 transgene in RL-m155 transgenic mice</title>
<p>As described in the Materials and Methods section, to examine the roles of miR-155 by gain of function, Rm155LG transgenic mice (i.e., Rm155LG mice) for the conditional overexpression of mouse miR-155 transgene mediated by Cre/lox P system were generated by us[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>].</p>
<p>To achieve global overexpression of miR-155, we crossed Rm155LG mice with EIIa-Cre mice. Procedure for producing RL-m155 transgenic mice (i.e., RL-m155 mice) which can globally overexpress miR-155 transgene and express mRFP and luciferase (Luc) reporter transgenes in multiple organs and tissues is detailedly illustrated in <xref ref-type="supplementary-material" rid="pgen.1006308.s001">S1A, S1D and S1E Fig</xref> exhibited whole-body fluorescence (b) and bioluminescence (c) imaging for newborn (<xref ref-type="supplementary-material" rid="pgen.1006308.s001">S1D Fig</xref>) and adult RL-m155 mice (<xref ref-type="supplementary-material" rid="pgen.1006308.s001">S1E Fig</xref>), respectively. We next determined the expression pattern of the mRFP and Luc transgenes in multiple organs and tissues taken from RL-m155 mice. Both red fluorescence and Luc signals were detected in tissue/organ samples including liver, skeletal muscle (SM), brown adipose tissue (BAT), white adipose tissue (WAT) and pancreas isolated from RL-m155 mice, but not in control littermates (<xref ref-type="fig" rid="pgen.1006308.g002">Fig 2A</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2A Fig</xref>). <xref ref-type="fig" rid="pgen.1006308.g002">Fig 2B</xref> demonstrated mRFP expression in the isolated islets of RL-m155 mice. qRT-PCR exhibited significant increases in miR-155 expression levels in liver, WAT, BAT, SM, pancreas and isolated islets of RL-m155 mice (<xref ref-type="fig" rid="pgen.1006308.g002">Fig 2C</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2B Fig</xref>). Additionally, global overexpression of miR-155 transgene did not alter the final body weight of RL-m155 mice (<xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2C–S2F Fig</xref>). RL-m155 mice displayed significantly reduced weight (<xref ref-type="fig" rid="pgen.1006308.g002">Fig 2D</xref>) of BAT, compared with their control mice.</p>
<fig id="pgen.1006308.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Global overexpression of miR-155 transgene in RL-m155 mice.</title>
<p><bold>(A)</bold> mRFP and luciferase (Luc) expression in multiple organs and tissues of RL-m155 mice. The left and right organ samples in each figure were obtained from control and RL-m155 mice, respectively. In this study, the non-transgenic littermates (i.e., wild-type littermates) were used as controls of RL-m155 transgenic mice. WAT: white adipose tissue; BAT: brown adipose tissue. Other details were described previously[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>]. <bold>(B)</bold> mRFP expression in the isolated islets of RL-m155 mice. <bold>(C)</bold> qRT-PCR analysis of miR-155 transgene expression in organs and tissues of RL-m155 mice. <bold>(D)</bold> Relative organ weight of RL-m155 mice vs. control mice.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec005">
<title>RL-m155 mice and miR-155 knockout (KO) mice exhibit the unaltered β-cell proliferation and hormone profiles in pancreas</title>
<p>As mentioned in “Introduction section”, miR-155 might be physiologically required for normal glucose homeostasis. This feature prompted us to firstly explore the influences of miR-155 on pancreatic β-cell proliferation, β-cell mass and β-cell function by using both RL-m155 mice and miR-155 knockout (KO) mice[<xref ref-type="bibr" rid="pgen.1006308.ref013">13</xref>]. We found that there was no difference in the morphology of the entire pancreas between control mice (i.e., non-transgenic littermates/wild-type littermates) and RL-m155 mice or between WT mice (i.e., wild-type C57BL/6J mice of the same age and sex) and miR-155 KO mice (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3A</xref>). H&amp;E staining and immunostaining of pancreatic sections with antibodies to insulin and to glucagon exhibited normal islet architecture in RL-m155 mice or miR-155 KO mice (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3B</xref>). Quantitative analysis also revealed no difference in insulin 1 (Ins1) and insulin 2 (Ins2) expression (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3C</xref>), and in total β-cell mass (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3D</xref>) between control and RL-m155 mice or between WT and miR-155 KO mice. Moreover, the number of BrdU- and Ki67-positive β-cells did not differ between control and RL-m155 mice or between WT and miR-155 KO mice (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3E and 3F</xref>). More importantly, there was also no difference in circulating insulin levels between control and RL-m155 mice (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4D</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3D Fig</xref>) or between WT and miR-155 KO mice (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5D</xref>), while glucose-stimulated insulin secretion (GSIS) tests revealed the unaltered insulin secretion following a glucose challenge between control and RL-m155 mice (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4G</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3G Fig</xref>) or between WT and miR-155 KO mice (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5I</xref>). Taken together, our findings support that in mouse pancreas, miR-155 don’t have obvious effects on the pancreatic morphology, β-cell proliferation, β-cell mass and β-cell function.</p>
<fig id="pgen.1006308.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g003</object-id>
<label>Fig 3</label>
<caption>
<title>RL-m155 mice and miR-155 knockout (KO) mice displayed the unaltered β-cell proliferation and hormone profiles in pancreas.</title>
<p><bold>(A)</bold> Morphology of the entire pancreas from RL-m155 mice and miR-155 KO mice. <bold>(B)</bold> Haematoxylin and eosin (H&amp;E), insulin and glucagon stainings of pancreatic islets in RL-m155 mice and miR-155 KO mice. <bold>(C)</bold> qRT-PCR analysis of Ins1 and Ins2 mRNA expression in pancreas tissue of RL-m155 mice and miR-155 KO mice. <bold>(D)</bold> Percentage of β-cell mass in RL-m155 mice and miR-155 KO mice. <bold>(E)</bold> BrdU and Ki67 stainings of pancreatic islets in RL-m155 mice and miR-155 KO mice. <bold>(F)</bold> Percentage of Ki67-positive cells in pancreatic islets in RL-m155 mice and miR-155 KO mice. In this study, the non-transgenic littermates/wild-type littermates [i.e., control (con) mice] were used as controls of RL-m155 mice, while wild-type C57BL/6J mice (i.e., WT) of the same age and sex were used as controls of miR-155<sup>–/–</sup>C57BL/6J mice.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g003" xlink:type="simple"/>
</fig>
<fig id="pgen.1006308.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Improved glucose tolerance and insulin sensitivity in RL-m155 mice.</title>
<p><bold>(A-C)</bold> Blood glucose concentrations in fed-state (A), 12-hour–fasted (B) and 24-hour–fasted (C) mice. Control mice: n = 9 (3m) and n = 8 (5m); RL-m155 mice: n = 7 (3m) and n = 9 (5m). <bold>(D)</bold> Serum insulin concentrations in fed-state and 12-hour–fasted mice (5m). <bold>(E-F)</bold> Glucose tolerance test (GTT) in 12-hour–fasted mice (E) and area under the curve (AUC) (F) for this GTT (E). <bold>(G)</bold> Serum insulin measurements performed in 12-hour–fasted mice (3m) during a GTT (E). <bold>(H)</bold> GTT in 12-hour–fasted control (Con) and RL-m155 mice. <bold>(I)</bold> AUC analysis for this GTT (H). <bold>(J)</bold> Insulin tolerance test (ITT) of 12-hour–fasted control and RL-m155 mice. <bold>(K)</bold> AUC analysis for this ITT (J). <bold>(L)</bold> ITT performed on 12-hour–fasted 5-month-old control and RL-m155 mice. <bold>(M)</bold> AUC calculated from mice in (L). Values are statistically significant at *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01 and <sup>#</sup><italic>P</italic>&lt;0.001.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g004" xlink:type="simple"/>
</fig>
<fig id="pgen.1006308.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g005</object-id>
<label>Fig 5</label>
<caption>
<title>miR-155 deficiency in mice led to hyperglycaemia and insulin resistance.</title>
<p><bold>(A-C)</bold> Blood glucose concentrations in fed-state (A), 12-hour–fasted (B) and 24-hour–fasted (C) miR-155 <sup>-/-</sup> mice (males: 3 m and females: 2m). WT mice: n = 10 (males) and n = 12 (females); miR-155 KO mice: n = 9 (males) and n = 10 (females). <bold>(D)</bold> Serum insulin concentrations in fed-state and 12-hour–fasted miR-155 <sup>-/-</sup> mice (3m). WT mice: n = 8; miR-155 KO mice: n = 8. <bold>(E-F)</bold> GTT in 12-hour–fasted miR-155 <sup>-/-</sup> mice (E) and area under the curve (AUC) (F) for this GTT (E). <bold>(G)</bold> GTT in 12-hour–fasted wild-type (WT) and miR-155 <sup>-/-</sup> mice. <bold>(H)</bold> AUC analysis for this GTT (G). <bold>(I)</bold> Serum insulin measurements performed in 12-hour–fasted mice (2m) during a GTT (G). <bold>(J)</bold> ITT of 12-hour–fasted WT and miR-155 <sup>-/-</sup> mice. <bold>(K)</bold> AUC analysis for this ITT (J). <bold>(L)</bold> ITT performed on 12-hour–fasted WT and miR-155 <sup>-/-</sup> mice. <bold>(M)</bold> AUC calculated from mice in (L). Values are statistically significant at *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01 and <sup>#</sup><italic>P</italic>&lt;0.001.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec006">
<title>Global overexpression of miR-155 improves glucose metabolism and insulin sensitivity in RL-m155 mice</title>
<p>Our above-mentioned results exhibited that the gain and loss of miR-155 function in mice didn’t have influences on pancreas morphology, islet architecture, β-cell proliferation and mass, and insulin and glucagon immunoreactivity (<xref ref-type="fig" rid="pgen.1006308.g003">Fig 3</xref>), leading us to further explore the roles of miR-155 in normal glucose homeostasis and insulin sensitivity using RL-m155 mice.</p>
<p>We observed that fasting and fed-state blood glucose levels were lower in RL-m155 male (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4A–4C</xref>) and female (<xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3A–S3C Fig</xref>) mice, whereas circulating insulin levels in the fed and fasted states did not differ between control and RL-m155 mice (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4D</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3D Fig</xref>). Glucose tolerance tests (GTTs) indicated that RL-m155 males and females cleared glucose more efficiently than controls (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4E, 4F, 4H and 4I</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3E and S3F Fig</xref>), suggesting an improved glucose tolerance in RL-m155 mice.</p>
<p>To evaluate insulin sensitivity of peripheral tissues, we performed insulin tolerance tests (ITTs) in RL-m155 mice. We noticed that RL-m155 mice were more sensitive to insulin than controls (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4J–4M</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3H–S3K Fig</xref>). To demonstrate that the lower blood glucose was due to an increase in peripheral tissue insulin sensitivity rather than an increase in secreted insulin, we performed glucose-stimulated insulin secretion (GSIS) tests, and found the unaltered insulin secretion following a glucose challenge between RL-m155 and control mice (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4G</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3G Fig</xref>), indicating that improved glucose metabolism in RL-m155 mice results from improved insulin sensitivity of peripheral tissues, but not increased insulin secretion. Taken together, analysis of GSIS, morphological and structure analysis of pancreatic islets, and determination of pancreatic β-cell mass and proliferation revealed no alterations (Figs <xref ref-type="fig" rid="pgen.1006308.g003">3</xref>, <xref ref-type="fig" rid="pgen.1006308.g004">4D and 4G</xref>, <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3D and S3G Fig</xref>), further supporting the hypothesis that improved glucose metabolism in RL-m155 mice arises primarily from improved insulin sensitivity of peripheral tissues rather than altered insulin secretion. This increase in insulin sensitivity of peripheral tissues of RL-m155 mice was verified by glucose uptake studies and molecular studies performed in insulin target organs (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6</xref>).</p>
<fig id="pgen.1006308.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Regulation of gene expression and insulin signalling by miR-155.</title>
<p><bold>(A)</bold> qRT-PCR analysis of the indicated gene expression in liver, WAT, BAT and SM of RL-m155 mice (4m). n = 5–10 mice per indicated genes. Values are statistically significant at *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01 and <sup>#</sup><italic>P</italic>&lt;0.001. <bold>(B)</bold> Western blot analysis of the expression of the indicated proteins in liver, adipose tissue and SM of RL-m155 mice (4m; n = 4). <bold>(C)</bold> Western blot analysis for SOCS1, SOCS3 and HDAC4 expression in miR-155-expressing 7402 cells, 7402 cells transfected with miR-155 inhibitor, and hepa1-6 cells transfected with miR-155 mimics or miR-155 inhibitor. <bold>(D)</bold> Representative Western-blot analysis of insulin-stimulated AKT and IRS-1 (Insulin receptor substrate 1) phosphorylation in liver, adipose tissue or SM of control and RL-m155 mice (5m). <bold>(E)</bold> Representative immunoblot analysis of insulin-stimulated AKT phosphorylation versus total AKT protein levels in hepa1-6 cells transfected with miR-155 mimics or miR-155 inhibitor. <bold>(F)</bold> In vitro evaluation of cellular <sup>18</sup>F-FDG uptake in miR-155-expressing 7402 cells, and hepa1-6 and C2C12 cells transiently transfected with miR-155 mimics by MicroPET/CT. The data on the fold changes in <sup>18</sup>F-FDG uptake between miR-155-expressing indicated cells and the corresponding control cells were shown in <xref ref-type="supplementary-material" rid="pgen.1006308.s009">S9 Fig</xref>. UC: untransfected cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g006" xlink:type="simple"/>
</fig>
<p>Additionally, the glucose metabolic performance in RL-155 mice maintained on an HFD (high-fat diet) was explored in this study. When mice were maintained on the chow diet, the RL-155 mice exhibited lower fasting serum glucose levels than control mice (<xref ref-type="supplementary-material" rid="pgen.1006308.s004">S4A Fig</xref>). The levels of fasting serum glucose were remarkably increased in mice on the HFD (<xref ref-type="supplementary-material" rid="pgen.1006308.s004">S4A Fig</xref>), but the serum glucose levels were significantly decreased in RL-155 mice relative to controls (<xref ref-type="supplementary-material" rid="pgen.1006308.s004">S4A Fig</xref>). When challenged with an i.p. glucose load, RL-155 mice on both chow and HFD displayed significantly improved glucose tolerance (<xref ref-type="supplementary-material" rid="pgen.1006308.s004">S4B Fig</xref>). ITT tests also illustrated improved insulin sensitivity in RL-155 mice on both chow and HFD (<xref ref-type="supplementary-material" rid="pgen.1006308.s004">S4C Fig</xref>). Thus, the global overexpression of miR-155 improves glucose tolerance and whole body insulin sensitivity, even when mice are challenged with a HFD.</p>
</sec>
<sec id="sec007">
<title>Impaired glucose metabolism in miR-155-deficient mice</title>
<p>To further examine the effects of loss of miR-155 function on blood glucose levels, glucose tolerance and insulin sensitivity, we used miR-155<sup>-/-</sup> mice to perform the following loss-of-function experiments. miR-155<sup>-/-</sup> mice exhibited increased blood glucose levels (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5A–5C</xref>), and unaltered plasma insulin concentrations (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5D</xref>). We observed impaired glucose tolerance (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5E–5H</xref>) and insulin resistance (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5J–5M</xref>) in miR-155<sup>-/-</sup> mice, which is contrary to the results of RL-m155 mice. Moreover, GSIS test revealed that serum insulin levels for mice of both genotypes were similar during GTT analysis (<xref ref-type="fig" rid="pgen.1006308.g005">Fig 5I</xref>), suggesting that impaired glucose metabolism in miR-155<sup>-/-</sup> mice results from reduced insulin sensitivity of peripheral tissues, but not decreased insulin secretion.</p>
<p>Collectively, analysis of GSIS, morphological and structure analysis of pancreatic islets, and determination of pancreatic β-cell mass and proliferation revealed no alterations (Figs <xref ref-type="fig" rid="pgen.1006308.g003">3</xref>, <xref ref-type="fig" rid="pgen.1006308.g005">5D and 5I</xref>), further supporting the hypothesis that impaired glucose metabolism in miR-155<sup>-/-</sup> mice arises primarily from insulin resistance of peripheral tissues rather than impaired insulin secretion. In summary, these observations exhibited that targeted disruption of miR-155 in mice specifically impairs glucose metabolism through induction of insulin resistance.</p>
</sec>
<sec id="sec008">
<title>miR-155 promotes cellular <sup>18</sup>F-FDG uptake in 7402, hepa1-6 and C2C12 cells</title>
<p>Diabetes and insulin resistance are associated with defects in glucose uptake, while GTTs and ITTs revealed a positive regulatory role of miR-155 in glucose tolerance and insulin sensitivity, further supporting the hypothesis that miR-155 might drive increased glucose uptake. To better characterize the role of miR-155 in regulating insulin sensitivity in liver and SM, we performed in vitro glucose uptake assays [i.e., <sup>18</sup>F-FDG (fluoro-D-glucose) uptake assays] using human hepatocellular carcinoma 7402 cells, and murine hepa1-6 and C2C12 cell lines. Here we designed a method for in vitro evaluation of cellular <sup>18</sup>F-FDG uptake by microPET/CT Inveon scanner, as described previously[<xref ref-type="bibr" rid="pgen.1006308.ref014">14</xref>]. <sup>18</sup>F-FDG microPET/CT scan was employed to reveal that miR-155-expressing 7402 cells, and hepa1-6 and C2C12 cells transiently transfected with miR-155 mimics exhibited significantly enhanced cellular <sup>18</sup>F-FDG uptake (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6F</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s009">S9 Fig</xref>), further supporting that miR-155 plays a positive role in regulating insulin sensitivity of peripheral tissues.</p>
</sec>
<sec id="sec009">
<title>Enhanced glycolysis and insulin-stimulated AKT phosphorylation in peripheral tissues of RL-m155 mice</title>
<p>To further investigate the mechanisms involved in enhanced insulin sensitivity of peripheral tissues in RL-m155 mice, we analyzed various molecules involved in glycolysis, glucose transporters and insulin sensitivity, and insulin-stimulated AKT phosphorylation in peripheral tissues (i.e., liver, adipose tissues and SM) of RL-m155 mice.</p>
<p>We hypothesized that increased glucose uptake induced by miR-155 overexpression (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6F</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s009">S9 Fig</xref>) represented an increase in glycolytic metabolism. To determine whether glycolysis might be altered in liver, WAT, BAT and SM of RL-m155 mice, we analyzed the expression of several key genes, such as Gck, pyruvate dehydrogenase kinase 4 (PDK4), pyruvate kinase M2 (PKM2) and activating transcription factor 4 (ATF4), involved in this process and whose expression is regulated by insulin in the liver[<xref ref-type="bibr" rid="pgen.1006308.ref015">15</xref>]. In RL-m155 mice, Gck expression was increased in liver and WAT, and pyruvate kinase M2 (PKM2) expression was enhanced in SM, while pyruvate dehydrogenase kinase 4 (PDK4) and activating transcription factor 4 (ATF4) expression were reduced in liver, WAT, BAT or SM (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6A</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s005">S5 Fig</xref>), suggesting that in RL-m155 mice, glycolysis is stimulated in these tissues examined by global miR-155 overexpression. Summarily, consistent with enhanced glucose uptake (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6F</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s009">S9 Fig</xref>), glucose utilization was promoted in liver, WAT, BAT and SM of RL-m155 mice, as indicated by increased (Gck and PKM2) or decreased (PDK4) expression of enzymes regulating glycolysis. Moreover, in RL-m155 mice, we observed the reduced expression of genes that encode glucose transporters (GLUT) such as GLUT2 and GLUT4 in liver (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6A</xref>), suggesting that the decreased expression of GLUT2 and GLUT4 can stop liver from releasing glucose to blood of RL-m155 mice. In contrast, we found the elevated expression of GLUT1 in WAT, BAT and SM, and GLUT4 in SM (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6A</xref>), indicating the enhanced absorption of glucose from blood to WAT, BAT and SM of RL-m155 mice. Together, these data suggest that global overexpression of miR-155 alters the metabolic state of these tissues, driving enhanced glucose uptake and favoring glycolytic metabolism.</p>
<p>Next, we analyzed the expression of known negative regulators (i.e., C/EBPβ[<xref ref-type="bibr" rid="pgen.1006308.ref016">16</xref>], HDAC4[<xref ref-type="bibr" rid="pgen.1006308.ref017">17</xref>] and PTEN[<xref ref-type="bibr" rid="pgen.1006308.ref018">18</xref>]) of insulin sensitivity and known inducers (i.e., SOCS1 and SOCS3[<xref ref-type="bibr" rid="pgen.1006308.ref019">19</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref020">20</xref>]) of insulin resistance. As expected, the global overexpression of miR-155 in mice reduced the expression of C/EBPβ, HDAC4, PTEN, SOCS1 and SOCS3 in liver, adipose tissue and SM of RL-m155 mice (Figs <xref ref-type="fig" rid="pgen.1006308.g006">6A, 6B</xref> and <xref ref-type="fig" rid="pgen.1006308.g007">7C</xref>), while our results from 7402 and hepa1-6 cells revealed that miR-155 negatively regulated the expression of C/EBPβ, HDAC4, SOCS1 and SOCS3 (Figs <xref ref-type="fig" rid="pgen.1006308.g006">6C</xref> and <xref ref-type="fig" rid="pgen.1006308.g007">7D</xref>), indicating that decreased expression of C/EBPβ, HDAC4, PTEN, SOCS1 and SOCS3 in insulin target organs of RL-m155 mice is consistent with increased whole-body insulin sensitivity.</p>
<fig id="pgen.1006308.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Downregulation of C/EBPβ, HDAC4 and PDK4 in cultured liver cells enhanced insulin-stimulated AKT activation and cellular <sup>18</sup>F-FDG uptake.</title>
<p><bold>(A)</bold> Sequence alignment of 3’-UTR of human (Hsa), mouse (Mmu), rhesus (Mml) and rat (Rno) C/EBPβ highlighting miR-155 binding site. <bold>(B)</bold> Both C/EBPβ and HDAC4 are target genes of miR-155. The luciferase reporter assay was performed using Hepa1-6 cells as described in the Materials and methods section. Values are statistically significant at <sup>#</sup><italic>P</italic>&lt;0.001. <bold>(C)</bold> Immunoblot analysis of C/EBPβ, HDAC4 and PDK4 expression in livers of RL-m155 mice and miR-155 <sup>-/-</sup> mice. <bold>(D)</bold> Western blot analysis for C/EBPβ, HDAC4 and PDK4 expression in miR-155-expressing 7402 cells, 7402 cells transfected with miR-155 inhibitor, and hepa1-6 cells transfected with miR-155 mimics or miR-155 inhibitor. <bold>(E)</bold> Cell extracts from hepa1-6 cells transfected with the indicated siRNA oligonucleotides were analyzed by immunoblotting with antibodies against the indicated proteins. <bold>(F)</bold> Western blot analysis of insulin-stimulated phosphorylation of AKT in hepa1-6 cells transfected with the indicated siRNA oligonucleotides. <bold>(G)</bold> In vitro evaluation of cellular <sup>18</sup>F-FDG uptake in hepa1-6 cells transfected with the indicated siRNA oligonucleotides by MicroPET/CT. The data on the fold changes in <sup>18</sup>F-FDG uptake between siRNA-transfected hepa1-6 cells and the corresponding control cells were shown in <xref ref-type="supplementary-material" rid="pgen.1006308.s010">S10 Fig</xref>. UC: untransfected cells</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g007" xlink:type="simple"/>
</fig>
<p>The metabolic effects of insulin, including insulin sensitivity, glucose uptake and glycogen synthesis, are mediated through activation of PI3K-AKT signaling pathway[<xref ref-type="bibr" rid="pgen.1006308.ref021">21</xref>]. The phosphorylation of AKT and IRS-1 (Insulin receptor substrate 1) was enhanced in liver, adipose tissue or SM of RL-m155 mice following stimulation by insulin (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6D</xref>). At a molecular level, improved insulin sensitivity in RL-m155 mice (<xref ref-type="fig" rid="pgen.1006308.g004">Fig 4</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s003">S3 Fig</xref>) was paralleled by increased insulin-stimulated phosphorylation of AKT and IRS-1 in liver, adipose tissue or SM (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6D</xref>). Together global miR-155 overexpression in mice enhances insulin sensitivity in liver, muscle and fat cells of RL-m155 mice.</p>
<p>Furthermore, Western-blot analysis revealed that insulin-stimulated AKT phosphorylation was increased in hepa1-6 cells transfected with miR-155 mimics (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6E</xref>), whereas insulin-stimulated AKT phosphorylation was reduced in hepa1-6 cells transfected with miR-155 inhibitor (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6E</xref>), suggesting that miR-155 is a positive regulator of insulin sensitivity. Summarily, our results indicate that miR-155 affects insulin's ability to positively regulate AKT phosphorylation in liver cells.</p>
</sec>
<sec id="sec010">
<title>Silencing of miR-155 targets (i.e. C/EBPβ and HDAC4) and C/EBPβ target PDK4 in cultured liver cells enhanced insulin-stimulated AKT activation and glucose uptake</title>
<p>Subsequently, we want to address the possible mechanisms by which miR-155 regulates insulin sensitivity and glucose metabolism. The putative or verified miR-155 target genes are summarized in <xref ref-type="supplementary-material" rid="pgen.1006308.s016">S5 Table</xref>. Among miR-155 target genes, C/EBPβ, HDAC4 and SOCS1 especially caught our attention. The reasons are as follows: (1) C/EBPβ, HDAC4 and SOCS1 genes harbor miR-155 binding site, which is conserved across different phyla (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7A</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s007">S7A Fig</xref>); (2) C/EBPβ[<xref ref-type="bibr" rid="pgen.1006308.ref016">16</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref022">22</xref>], HDAC4[<xref ref-type="bibr" rid="pgen.1006308.ref023">23</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref024">24</xref>] and SOCS1[<xref ref-type="bibr" rid="pgen.1006308.ref025">25</xref>] are negative regulators of blood glucose and insulin sensitivity in mice, and SOCS1 is characterized as a positive mediator of insulin resistance[<xref ref-type="bibr" rid="pgen.1006308.ref025">25</xref>]; (3) SOCS1 is a negative regulator of IRS-1/PI3K/AKT insulin pathway[<xref ref-type="bibr" rid="pgen.1006308.ref026">26</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref027">27</xref>].</p>
<p>The 3’-UTRs of C/EBPβ (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7B</xref>), HDAC4 (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7B</xref>) and SOCA1 (<xref ref-type="supplementary-material" rid="pgen.1006308.s007">S7B Fig</xref>) mRNA contain complementary site for the seed region of miR-155, respectively. We generated reporter constructs in which the luciferase coding sequence was fused to the 3′-UTRs of these genes. Measurements of luciferase activity in hepa1-6 cells transfected with miR-155 mimics plus reporter plasmid containing the wild-type 3’-UTRs of C/EBPβ or HDAC4 exhibited a significant reduction of luciferase activity (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7B</xref>), respectively. In contrast, transient transfection of wild-type C/EBPβ-Luc reporter or HDAC4-Luc reporter with miR-155 mimics plus inhibitor into hepa1-6 cells could fully reverse the miR-155-induced decrease in luciferase activity (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7B</xref>).</p>
<p>To examine the influences of miR-155 on endogenous expression of these miR-155 targets, we firstly determined their expression in the livers of RL-m155 mice and miR-155<sup>-/-</sup> mice. As expected, mRNA and protein levels of C/EBPβ, HDAC4 and SOCS1, and C/EBPβ target PDK4 in the liver of RL-m155 mice was remarkably down-regulated (Figs <xref ref-type="fig" rid="pgen.1006308.g006">6A, 6B</xref> and <xref ref-type="fig" rid="pgen.1006308.g007">7C</xref>, <xref ref-type="supplementary-material" rid="pgen.1006308.s005">S5</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s007">S7C</xref> Figs), whereas C/EBPβ, HDAC4, SOCS1 and PDK4 protein levels in the livers of miR-155<sup>-/-</sup> mice were significantly up-regulated (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7C</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s007">S7C Fig</xref>). Moreover, miR-155 overexpression in 7402 and hepa1-6 cells resulted in significant reduction of endogenous C/EBPβ, HDAC4, SOCS1 and PDK4 (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6C</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s008">S8 Fig</xref>). Conversely, 7402 and hepa1-6 cells transfected with miR-155 inhibitor exhibited the enhanced expression of C/EBPβ, HDAC4, SOCS1 and PDK4 (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6C</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s008">S8 Fig</xref>). Therefore, miR-155 negatively regulates it targets C/EBPβ, HDAC4 and SOCS1 expression, and C/EBPβ target PDK4 expression. More importantly, these aforementioned results suggest that C/EBPβ and HDAC4 are direct targets of miR-155. Furthermore, SOCS1 is identified as a direct target gene of miR-155 in human and mouse cells[<xref ref-type="bibr" rid="pgen.1006308.ref028">28</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref030">30</xref>].</p>
<p>To directly examine potential roles for C/EBPβ and HDAC4, and C/EBPβ target PDK4 in control of insulin-stimulated AKT activation and glucose uptake, we analyzed AKT phosphorylation and glucose uptake in insulin-stimulated hepa1-6 cells transfected with short interfering RNAs (siRNAs) directed to mouse C/EBPβ (siC/EBPβ), HDAC4 (siHDAC4) and PDK4 (siPDK4), respectively. Western-blot and qRT-PCR analysis showed successful reduction of C/EBPβ, HDAC4 and PDK4 expression in cells transfected with siC/EBPβ, siHDAC4 and siPDK4, respectively (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7E</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s008">S8 Fig</xref>). siRNA-mediated silencing of C/EBPβ, HDAC4 or PDK4 in hepa1-6 cells enhanced insulin-stimulated AKT phosphorylation (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7F</xref>), respectively, similar to what was observed upon miR-155 overexpression (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6E</xref>). Taken together, our results indicate that C/EBPβ, HDAC4 or PDK4 affects insulin's ability to regulate AKT phosphorylation in liver cells. More importantly, our findings suggest that C/EBPβ and HDAC4 are involved in miR-155-mediated insulin-stimulated AKT phosphorylation in liver cells. Moreover, siRNA-mediated knockdown of miR-155 target genes (C/EBPβ and HDAC4) and C/EBPβ target gene PDK4 mimicked miR-155-induced glucose uptake in hepa1-6 cells (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7G</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s010">S10 Fig</xref>), which is similar as the results caused by miR-155 overexpression (<xref ref-type="fig" rid="pgen.1006308.g006">Fig 6F</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s009">S9 Fig</xref>), suggesting that C/EBPβ and HDAC4 are involved in miR-155-induced glucose uptake.</p>
</sec>
</sec>
<sec id="sec011" sec-type="conclusions">
<title>Discussion</title>
<p>Altered expression of miRNAs in insulin-sensitive tissues of T2D patients suggests a potential role for these small RNA molecules in the complications associated with the diabetic condition[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref031">31</xref>]. Moreover, increasing evidence has revealed that miRNAs are also present in a stable form in several body fluids, including blood, suggesting that extracellular miRNAs hold promise to serve as novel biomarkers for metabolic disorders and/or their associated complications[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref031">31</xref>]. To date, a number of studies have revealed an altered profile of circulating miRNAs in various metabolic diseases such as T2D[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref031">31</xref>]. miR-155 expression in PBMCs from T2D patients was decreased[<xref ref-type="bibr" rid="pgen.1006308.ref011">11</xref>], which is consistent with our findings that the downregulated miR-155 levels were found in serum from T2D patients. Moreover, circulating levels of miR-155 were downregulated in plasma from patients with coronary artery disease plus diabetes[<xref ref-type="bibr" rid="pgen.1006308.ref032">32</xref>], while miR-155 expression was reduced in diabetic kidney, heart, aorta, PBMCs and sciatic nerve of diabetic rats[<xref ref-type="bibr" rid="pgen.1006308.ref033">33</xref>]. But the causal relationship between miR-155 dysregulation and diabetes or diabetes complications remains unknown, and further investigations are needed to precisely clarify the roles of miR-155 in diabetes and diabetes complications, and the underlying mechanisms.</p>
<p>Moreover, it is hard to exactly tell where the serum miRNAs are from because it is difficult to get biopsy samples to identify which specific tissue changes blood miRNA levels in these T2D patients. It is well known that animal and human living tissues can release the intracellular miRNAs into the circulation[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref031">31</xref>]. When human tumors were implanted in mice, specific human tumor-derived miRNAs have been detected in plasma[<xref ref-type="bibr" rid="pgen.1006308.ref034">34</xref>], while the circulating myocardial-derived miRNAs might be useful as potential biomarkers for infarction[<xref ref-type="bibr" rid="pgen.1006308.ref035">35</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref039">39</xref>]. Indeed, circulating miRNAs can provide an integrated view of the metabolic profile of the T2D patients because all insulin-sensitive tissues release the packaged miRNA into blood[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref031">31</xref>]. In the T2DM rat model (obese high fat diet animals treated with streptozotocin), the rat blood miRNA profile was clustered closely to those from the rat insulin-sensitive tissues (skeletal muscle, adipose tissue and liver) and pancreas[<xref ref-type="bibr" rid="pgen.1006308.ref040">40</xref>]. Additionally, most of the miRNA changes detected in these tissues involved in the insulin signaling pathway were also detected in blood miRNA profile[<xref ref-type="bibr" rid="pgen.1006308.ref040">40</xref>]. Thus, we suspect that the decrease of miR-155 expression in insulin-sensitive tissues (i.e., liver, adipose tissue and skeletal muscle) may cause the decreased blood miR-155 level in diabetic patients. In future study, we can prove it by observing the changes of miR-155 expression in different insulin-sensitive tissues and blood during the development of diet-induced obesity and diabetes in mice.</p>
<p>In this study, when globally overexpressed in mice, miR-155 resulted in hypoglycaemia, improved glucose tolerance and enhanced insulin sensitivity of peripheral tissues, whereas mice lacking miR-155 developed hyperglycemia, glucose intolerance and insulin resistance, suggesting the beneficially regulatory roles of miR-155 in glucose homeostasis. Increased insulin sensitivity and improved glucose tolerance in RL-m155 mice could be explained, at least in part, by enhanced glucose uptake through elevated phosphorylation of AKT, and by enhanced glycolysis manifested via upregulation of Gck and PKM2, and downregulation of PDK4. All in all, our findings firstly demonstrate that miR-155 regulates multiple aspects of glucose metabolism. More importantly, our findings fully reveal that the gain of miR-155 function leads to hypoglycemia and improved glucose tolerance through induction of insulin insensitivity in peripheral tissues, thereby improving whole-body glucose metabolism.</p>
<p>Up to now, there have been very few miRNAs, such as miR-130a-3p[<xref ref-type="bibr" rid="pgen.1006308.ref041">41</xref>], miR-26a[<xref ref-type="bibr" rid="pgen.1006308.ref042">42</xref>] and miR-155 (this study), to be found to act as positive regulators of glucose tolerance and insulin sensitivity in vivo. Interestingly, our study revealed that miR-155 overexpression in mice fed a conventional diet resulted in the aforementioned multiple metabolic phenotypes, whereas miR-26a overexpression led to reduced blood-glucose levels, better glucose tolerance and insulin sensitivity, and decreased hepatic glucose production in high-fat diet-fed mice, but not in conventional diet–fed mice[<xref ref-type="bibr" rid="pgen.1006308.ref042">42</xref>], suggesting that miR-155 and miR-26a might play different roles in regulating glucose metabolism.</p>
<p>As shown in <xref ref-type="fig" rid="pgen.1006308.g008">Fig 8</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s011">S11 Fig</xref>, this study uncovers partially molecular mechanisms underlying miR-155’s functions in the above-mentioned multiple metabolic phenotypes. miRNAs are critical modulators of glucose and lipid metabolism by negatively regulating the expression of multiple target genes[<xref ref-type="bibr" rid="pgen.1006308.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref003">3</xref>]. Our studies revealed that the expression of miR-155 targets (i.e. C/EBPβ, HDAC4 and SOCS1) and PDK4, a direct target of C/EBPβ[<xref ref-type="bibr" rid="pgen.1006308.ref043">43</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref044">44</xref>], were negatively regulated by miR-155, and C/EBPβ knockdown reduced PDK4 expression in hepa1-6 cells. Both C/EBPβ<sup>–/–</sup>mice[<xref ref-type="bibr" rid="pgen.1006308.ref016">16</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref022">22</xref>] and PDK4<sup>–/–</sup>mice[<xref ref-type="bibr" rid="pgen.1006308.ref045">45</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref046">46</xref>] display hypoglycemia and increased insulin sensitivity. PDK4 plays a crucial role in glucose utilization by negatively regulating pyruvate dehydrogenase complex (PDC) activity[<xref ref-type="bibr" rid="pgen.1006308.ref043">43</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref044">44</xref>]. Furthermore, the activation of AKT signaling by insulin suppresses PDK4 expression[<xref ref-type="bibr" rid="pgen.1006308.ref043">43</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref044">44</xref>]. These aforementioned data indicate that the metabolic phenotypes in mice with loss of function of C/EBPβ[<xref ref-type="bibr" rid="pgen.1006308.ref016">16</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref022">22</xref>] or PDK4[<xref ref-type="bibr" rid="pgen.1006308.ref045">45</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref046">46</xref>] are similar to what was observed upon miR-155 overexpression in mice, and are opposite to what we found in miR-155<sup>-/-</sup> mice. Therefore, these observations support that miR-155 might negatively regulate PDK4 via negatively modulating C/EBPβ expression, thereby resulting in the aforementioned metabolic phenotypes (<xref ref-type="fig" rid="pgen.1006308.g008">Fig 8</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s011">S11 Fig</xref>).</p>
<fig id="pgen.1006308.g008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006308.g008</object-id>
<label>Fig 8</label>
<caption>
<title>A proposed model on the positive roles of miR-155 in glucose metabolism by coordinated regulation of multiple genes.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.g008" xlink:type="simple"/>
</fig>
<p>Defects in peripheral tissue glucose uptake are associated with insulin resistance. We found that miR-155 overexpression decreased miR-155 target gene HDAC4 expression and increased GLUT4 levels in SM of RL-m155 mice, and increased glucose uptake in cells (including C2C12 cells) examined, similar to what was observed upon HDAC4 siRNA. HDAC4 inhibits the expression of GLUT4, a direct target of HDAC4[<xref ref-type="bibr" rid="pgen.1006308.ref047">47</xref>]. HDAC4 siRNA increased GLUT4 levels and glucose uptake in adipocytes[<xref ref-type="bibr" rid="pgen.1006308.ref048">48</xref>]. Loss of the class IIa HDACs (HDAC4,5, and 7) in murine liver resulted in lowered blood glucose levels, increased hepatic glycogen storage, improved glucose tolerance and insulin sensitivity in mice[<xref ref-type="bibr" rid="pgen.1006308.ref023">23</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref024">24</xref>]. Together, these data support this hypothesis that miR-155 upregulates GLUT4 expression through downregulating HDAC4 expression, thereby leading to enhanced glucose uptake in insulin-sensitive tissues (i.e., SM), strongly supporting that miR-155 play a positive role in regulating insulin sensitivity of peripheral tissues, at least in part, through suppressing HDAC4 expression (<xref ref-type="fig" rid="pgen.1006308.g008">Fig 8</xref>).</p>
<p>SOCS1, a negative regulator of blood glucose and insulin sensitivity in mice[<xref ref-type="bibr" rid="pgen.1006308.ref019">19</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref020">20</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref025">25</xref>], blocks IRS-1/PI3K/AKT insulin pathway by ubiquitin-mediated degradation of IRS-1[<xref ref-type="bibr" rid="pgen.1006308.ref026">26</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref027">27</xref>].</p>
<p>Our results revealed that miR-155 negatively regulated its target gene SOCS1 expression in insulin-sensitive tissues and liver cells, and miR-155 overexpression led to enhanced IRS-1 phosphorylation and AKT phosphorylation in SM and adipose tissue of RL-m155 mice after insulin treatment. Collectively, the findings prompt us to speculate that miR-155 might activate IRS-1/PI3K/AKT insulin pathway by inhibiting SOCS1 expression, which at least partially contributes to the above-mentioned metabolic phenotypes (<xref ref-type="fig" rid="pgen.1006308.g008">Fig 8</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s011">S11 Fig</xref>).</p>
<p>As shown in <xref ref-type="fig" rid="pgen.1006308.g008">Fig 8</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s011">S11 Fig</xref>, here we provide a working hypothesis that explains the roles of miR-155 in inducing multiple phenotypic changes in mice and the underlying mechanisms. Although we cannot rule out the possibility that other known (such as CES3)[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>] and unknown target genes of miR-155 (<xref ref-type="supplementary-material" rid="pgen.1006308.s016">S5 Table</xref>) contribute to glucose metabolism, we speculate that the coordinated regulation of the miR-155 target genes (C/EBPβ, HDAC4 and SOCS1) could profoundly alter gene expression profiling related with glucose metabolism, thereby modulating the above-mentioned multiple metabolic phenotypes. These results from this study and the recent report[<xref ref-type="bibr" rid="pgen.1006308.ref042">42</xref>] demonstrate that a single miRNA, such as miR-155 (this study) and miR-26a[<xref ref-type="bibr" rid="pgen.1006308.ref042">42</xref>], can regulate multiple metabolic phenotypes in vivo by coordinated regulation of multiple genes. These effects of miR-155 could be greatly consolidated and augmented by crosstalk between glucose metabolism and insulin signaling, which indicates that a small change in miR-155 expression can sometimes have a large physiological effect on metabolic phenotypes. In line with this idea, a minor or modest increase in miR-155 expression in mice was sufficient to induce multiple phenotypic changes.</p>
<p>Besides these aforementioned miR-155 targets, many metabolic genes that lack predicted miR-155 target sites exhibit the altered expression upon modulation of miR-155 expression.</p>
<p>These glucose metabolism-related genes are involved in glycogen metabolism (Gys2), glycolysis (Gck, PDK4, PKM2 and Ldha), glucose transporters (GLUT1, GLUT2, GLUT4, Slc1a2 and Slc3a2). It is likely that these differentially expressed genes act the downstream of target genes of miR-155. Indeed, as mentioned above, PDK4[<xref ref-type="bibr" rid="pgen.1006308.ref043">43</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref044">44</xref>] is C/EBPβ target gene, and GLUT4[<xref ref-type="bibr" rid="pgen.1006308.ref047">47</xref>] is a target gene of HDAC4.</p>
<p>Furthermore, there are several lines of evidence that miR-155 is also involved in adipocyte differentiation[<xref ref-type="bibr" rid="pgen.1006308.ref049">49</xref>], adipogenesis[<xref ref-type="bibr" rid="pgen.1006308.ref050">50</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref051">51</xref>] and lipid metabolism[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref052">52</xref>]. In vivo, miR-155 overexpression in transgenic mice caused the reduction of brown adipose tissue mass and impairment of brown adipose tissue function, whereas, miR-155 inhibition in mice resulted in a hyperactive brown adipose tissue and induced a brown adipocyte-like phenotype ('browning') in white adipocytes[<xref ref-type="bibr" rid="pgen.1006308.ref049">49</xref>]. The ectopic expression of miR-155 significantly inhibited adipogenesis in vitro[<xref ref-type="bibr" rid="pgen.1006308.ref050">50</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref051">51</xref>]. Our previous report revealed that liver-specific overexpression of miR-155 transgene resulted in significantly reduced levels of serum total cholesterol, triglycerides (TG) and high-density lipoprotein (HDL), as well as remarkably decreased contents of hepatic lipid, TG, HDL and free fatty acid in Rm155LG/ Cre transgenic mice[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>], indicating that miR-155 negatively modulates levels of hepatic and serum lipid compositions, and displays lipid-lowering activity in mice. In summary, these findings from this study and other studies demonstrate the importance of miR-155 in the multiple aspects of glucose metabolism and insulin signaling, lipid metabolism and adipocyte differentiation through regulation of critical metabolic genes.</p>
<p>Furthermore, these findings from this study and other studies revealed the decreased BAT mass and function in miR-155 transgenic mice, and the preliminary data from this study displayed the enhanced glucose uptake &amp; glycolysis and insulin-stimulated AKT phosphorylation in BAT of RL-m155 mice. But the influences of the decreased BAT mass and function caused by miR-155 overexpression in mice on glucose metabolism (including whole-body insulin sensitivity) in mice remains unknown. In future study, given the important roles of BAT in obesity and glucose metabolism, the conditional gain-of-function (using Rm155LG transgenic mice[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>]) and loss-of-function (using miR-155 floxed mice[<xref ref-type="bibr" rid="pgen.1006308.ref053">53</xref>]) of miR-155 in BAT of mice will be employed to fully explore the roles of the miR-155 overexpression-induced decreased BAT mass and function on glucose metabolism (including whole-body insulin sensitivity) in mice.</p>
<p>Additionally, further experiments in primates will be required to evaluate the roles of miR-155 in improving glucose tolerance and insulin sensitivity, and subsequently lowering blood glucose levels, which will be helpful investigations in assessing the prospects for therapeutical miR-155 gain of function by using miR-155 mimics to treat insulin resistance and T2DM.</p>
<p>Besides the multifunctions of miR-155, it is important to pay attention to the following aspects. First, miR-155 regulates multiple components of glucose metabolism. Second, our results from this study and previous report[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>] reveal the blood glucose-lowering activity and lipid-lowering activity of miR-155. Third, miR-155 transgene is universally expressed at relatively low levels in liver, WAT, BAT, SM, pancreas and isolated islets of RL-m155 mice, and in liver of Rm155LG/Alb-Cre mice[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>], while miR-155 transgene is expressed at relatively high levels in brain, testis and heart of RL-m155 mice. But our results indicate that the relatively low levels of miR-155 transgene expression in major insulin target organs or tissues (liver, adipose tissues and SM) are sufficient to induce phenotypes described above and observed in our paper[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>], indicating that modest overexpression of miR-155 could be safe; in support of this idea, physiological and pathological side effects of miR-155 overexpression were not observed in RL-m155 mice and Rm155LG/Alb-Cre mice of up to one years of age. Thus, the low and modest miR-155 overexpression can decrease the risk of tumorigenesis. Four, the global (this study) or hepatocyte-specific[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>] overexpression of miR-155 in mice does not induce weight gain, avoiding the major side effect of increasing insulin sensitivity for diabetes therapies[<xref ref-type="bibr" rid="pgen.1006308.ref054">54</xref>]. Given the potent roles of miR-155 in the above observations as well as lipid metabolism[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref052">52</xref>], these findings suggest miR-155 as a promising novel target for treatment of T2DM.</p>
<p>In summary, our findings firstly reveal that (1) miR-155 regulates multiple aspects of normal glucose metabolism and insulin signaling through coordinated regulation of critical metabolic genes in mice; (2) miR-155 is a positive regulator of insulin sensitivity; and (3) miR-155 is physiologically required for normal blood glucose homeostasis in mice. In addition, miR-155 displays blood glucose-lowering activity and lipid-lowering activity in mice. More importantly, our observations strongly support that miR-155 is entitled to control all 3 hallmarks of T2DM, namely insulin resistance, excessive HGP which primarily results from sustained gluconeogenesis[<xref ref-type="bibr" rid="pgen.1006308.ref055">55</xref>], and elevated lipid synthesis. Although the mechanism(s) of how miR-155 controls glucose homeostasis clearly requires further investigation, these current findings suggest that the therapeutical gain of miR-155 function may become a beneficial strategy for glycemic control to treat insulin resistance and T2DM. Summarily, miR-155 represents a promising target for the treatment of insulin resistance and diabetes.</p>
</sec>
<sec id="sec012" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec013">
<title>Animal studies with miR-155 transgenic mice and miR-155 <sup>-/-</sup> mice</title>
<p>The homozygous EIIa-Cre transgenic mice (FVB/N-Tg(EIIa-cre)C5379Lmgd/J) and the wild-type FVB/N mice were obtained from <ext-link ext-link-type="uri" xlink:href="http://www.nicemice.cn/en_index.htm" xlink:type="simple">Model Animal Research Center of Nanjing University</ext-link>. The wildtype <ext-link ext-link-type="uri" xlink:href="http://211.147.240.53/census/jsp/show/listZiyuan.jsp?pinxi_id=22" xlink:type="simple">C57BL/6</ext-link>J mice were purchased from Center of Experimental Animals, Southern Medical University.</p>
<p>Rm155LG transgenic mice that can conditionally overexpress mouse miR-155 transgene mediated by Cre/lox P system have been generated on C57BL/6 background, as previously described[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>]. RL-m155 transgenic mice have been generated on FVB background, as described in <xref ref-type="supplementary-material" rid="pgen.1006308.s001">S1</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2</xref> Figs miR-155<sup>–/–</sup>C57BL/6J mice (B6.Cg-Mir155<sup>tm1.1Rsky</sup>/J; Stock Number: 007745) were purchased from Jackson laboratory[<xref ref-type="bibr" rid="pgen.1006308.ref013">13</xref>].</p>
<p>This study was approved by the Southern Medical University (approval number: L2015079) and was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Southern Medical University. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Southern Medical University. All surgery was performed under sodium pentobarbital anesthesia, all efforts were made to minimize animal suffering and the number of animals used was kept to a minimum by the experimental design.</p>
</sec>
<sec id="sec014">
<title>Patients and healthy subjects</title>
<p>Newly diagnosed T2DM patients (n = 30) and healthy controls (n = 30) were recruited at Department of Endocrinology, the Second Affiliated Hospital of Guangzhou Medical University. Patients in this study were diagnosed according to the World Health Organization (WHO) diagnostic criteria[<xref ref-type="bibr" rid="pgen.1006308.ref056">56</xref>]. To minimize the likelihood of misclassification of autoimmune diabetes as T2DM, the subjects with any of four auto-antibodies (GADA, IA-2A, ICA, or IAA) were excluded from T2DM. Non-diabetes subjects as control were healthy subjects without any family history of diabetes, and with fasting plasma glucose levels below 6.1 mM and 2 h post-load plasma glucose concentrations &lt;7.8 mM after a 75 g oral glucose tolerance test. The present study was approved by the Hospital Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University (Project No. 015027).</p>
<p>Insulin resistance (HOMA-IR) and β-cell function (HOMA-β) as indicators of homeostasis model assessment were utilized to assess the status of insulin action and insulin secretion in subjects, respectively. HOMA-IR = FPG (mmol/l)* FINS (mU/ml)/22.5, HOMA-β = 20* FINS (mU/ml)/[FPG (mmol/l)-3.5][<xref ref-type="bibr" rid="pgen.1006308.ref057">57</xref>].</p>
</sec>
<sec id="sec015">
<title>Quantitative RT-PCR (qRT-PCR)</title>
<p>To quantitate miRNA and mRNA expression, total RNA was extracted from cells or from various tissues of transgenic mice and gene knockout mice with the use of TRIzol reagent (TaKaRa). The isolation of microRNA from the serum of healthy subjects and T2D patients was performed using the microRNA RNeasy Mini Kit (Exiqon) following the manufacturer’s recommendations. qRT-PCR was performed with standard methods on Stratagene Mx3005P qRT-PCR System, which are described in detail previously[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>]. The primers used for the amplification of the indicated genes were listed in <xref ref-type="supplementary-material" rid="pgen.1006308.s012">S1</xref>–<xref ref-type="supplementary-material" rid="pgen.1006308.s014">S3</xref> Tables.</p>
</sec>
<sec id="sec016">
<title>Organ and tissue fluorescence imaging</title>
<p>mRFP expression in the postnatal organs and tissues of RL-m155 transgenic mice was assayed under stereo fluorescent microscope (Nikon, AZ100), as described previously[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref058">58</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref059">59</xref>].</p>
</sec>
<sec id="sec017">
<title>Ex vivo organ optical imaging of firefly luciferase (Luc) activity</title>
<p>Bioluminescence imaging for multiple organs and tissues obtained from RL-m155 transgenic and control mice was measured using the IVIS LuminaIIimaging system (Xenogen Corp., Alameda, CA), as described previously[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>, <xref ref-type="bibr" rid="pgen.1006308.ref058">58</xref>].</p>
</sec>
<sec id="sec018">
<title>Metabolic studies</title>
<p>For glucose tolerance test (GTT), mice were fasted overnight for 12h, and then injected intraperitoneally with glucose (2g/kg body weight). For insulin tolerance test (ITT), mice were fasted overnight for 6h, and then injected intraperitoneally with human insulin (Novo Nordisk) at a dose of 0.75IU/kg body weight. Blood glucose levels were measured from mouse tail vein with an automatic glucometer (One Touch Lifescan, Johnson &amp; Johnson, USA) before glucose and insulin injection and at the indicated time after injection. Serum insulin levels were measured by enzyme-linked immunosorbent assay according to vendor’s instructions (Millipore Rat/Mouse Insulin ELISA Kit, EZRMI-13K).</p>
</sec>
<sec id="sec019">
<title>Histological and immunohistological examinations</title>
<p>For immunohistology, mouse tissues were fixed in 4% paraformaldehyde at 4°C overnight and embedded in paraffin as described previously[<xref ref-type="bibr" rid="pgen.1006308.ref060">60</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref062">62</xref>], then followed by hematoxylin and eosin staining (H&amp;E staining) according to standard procedures. Afterward, the sections or slides were stained with <ext-link ext-link-type="uri" xlink:href="http://www.baidu.com/link?url=-kzmogtsGglcJSsyDlLM0VTx8IqlUA87M-ZylsF1AIcV3JBgP2pxLrP9vK6ewc7Nnm2a1HMFW27pRRbRfi6oy_&amp;ie=utf-8&amp;f=8&amp;tn=baidu&amp;wd=IHC%20or%20immunofluorescence&amp;bs=as%20described%20in%20detail%20previously" xlink:type="simple">immunohistochemistry (IHC)</ext-link>. The primary antibodies are anti-insulin [1:100, Cell Signaling Technology (CST), USA], anti-glucagon (1:100; CST, USA), anti-Ki67 (1:300; Abcam) and anti-BrdU (1:50; GE Healthcare).</p>
</sec>
<sec id="sec020">
<title>Western blot analysis</title>
<p>Western blot was performed with standard methods, which are described in detail previously[<xref ref-type="bibr" rid="pgen.1006308.ref060">60</xref>–<xref ref-type="bibr" rid="pgen.1006308.ref064">64</xref>]. For origin and description of all antibodies used in this study, see <xref ref-type="supplementary-material" rid="pgen.1006308.s015">S4 Table</xref>.</p>
</sec>
<sec id="sec021">
<title>miRNAs transient transfection</title>
<p>The mouse or human miR-155 mimics, mimics control, miR-155 inhibitor and inhibitor control were purchased from RiboBio Co., Ltd (Guangzhou, China). miRNAs were transiently transfected into cells (including hepa1-6, 7402 and C2C12 cells) at a working concentration of 100nM using Lipofectamine 2000 reagent (Invitrogen) in accordance with the manufacturer’s procedure. All RNA oligonucleotides treatments proceeded for 48-72h. The effect of in vitro overexpression of miR-155 by using miRNA mimics and the repression of endogenous miR-155 expression by a miR-155 inhibitor on insulin-stimulated AKT phopshorylation was examined in hepa1-6 cells. After stimulation with 50IU/L human insulin (Novo Nordisk) for 15 min at 37°C (<xref ref-type="supplementary-material" rid="pgen.1006308.s006">S6 Fig</xref>), the medium was removed and the cells were immediately lysed with ice-cold lysis buffer.</p>
</sec>
<sec id="sec022">
<title>Dual luciferase reporter assay</title>
<p>Mouse hepatoma (Hepa1-6) cells were obtained from the Cell Bank of Chinese Academy of Sciences Shanghai Institute of Cell Biology. Hepa1-6 cells were seeded in triplicate in 96-well plates and cultured overnight. The dual luciferase reporter gene plasmids [pLuc-C/EBPβ-3’-UTR-wt or pLuc-HDAC4-3’-UTR-wt (Kangbio, Shenzhen, China)] were cotransfected into hepa1-6 cells with the miR-155 mimics, mimics control or miR-155 mimics plus miR-155 inhibitor using Lipofectamine 2000 Reagent (Invitrogen), respectively. Luciferase and Renilla activities were assayed 48 hours after transfection using the Dual Luciferase Reporter Assay Kit (Promega) following the manufacturer’s instructions.</p>
</sec>
<sec id="sec023">
<title>RNA interference experiments</title>
<p>An siRNA targeting mouse PDK4 (siG140711153320), an siRNA targeting mouse C/EBPβ (siG09723100032), an siRNA targeting mouse HDAC4 (siB1271190307) and a control siRNA were purchased from RiboBio Co., Ltd (Guangzhou, China). Western-blot and qRT-PCR analysis showed successful reduction of C/EBPβ, HDAC4 and PDK4 expression in cells transfected with siC/EBPβ, siHDAC4 and siPDK4, respectively (<xref ref-type="fig" rid="pgen.1006308.g007">Fig 7E</xref> and <xref ref-type="supplementary-material" rid="pgen.1006308.s008">S8 Fig</xref>). Hepa1-6 cells were transfected with 50nM siRNA-PDK4, siRNA-C/EBPβ, siRNA-HDAC4 or scrambled control siRNAs using Lipofectamine 2000 (Invitrogen) for 48-72h according to the manufacturer's instructions. The effect of PDK4, C/EBPβ or HDAC4 knockdown on insulin-stimulated AKT phopshorylation was examined in hepa1-6 cells. After stimulation with 50IU/L human insulin (Novo Nordisk) for 15 min at 37°C (<xref ref-type="supplementary-material" rid="pgen.1006308.s006">S6 Fig</xref>), the medium was removed and the cells were immediately lysed with ice-cold lysis buffer for western-blot.</p>
</sec>
<sec id="sec024">
<title>Cellular <sup>18</sup>F-FDG uptake</title>
<p>Cells were seeded on a 24-well plate (2×10<sup>5</sup>/well) for microPET/CT scan. After 24 h, culture medium was replaced, and cells were incubated in fresh medium containing <sup>18</sup>F-FDG (about 20μCi/well) for 1h. Then, cells were washed with phosphate-buffered saline five times, and image was obtained by microPET/CT Inveon scanner (Siemens).</p>
</sec>
<sec id="sec025">
<title>Statistical analysis</title>
<p>All data were presented as mean±SD. Statistical analysis was performed using a SPSS 13.0 software package. Values are statistically significant at *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01 and <sup>#</sup><italic>P</italic>&lt;0.001.</p>
</sec>
</sec>
<sec id="sec026">
<title>Supporting Information</title>
<supplementary-material id="pgen.1006308.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Generation of RL-m155 transgenic mice.</title>
<p><bold>(A)</bold> Schematic strategy for generating RL-m155 transgenic mice. Procedure for producing transgenic mice which can globally overexpress mouse miR-155 transgene in multiple organs and tissues of mice was detailedly illustrated in S1A Fig. Briefly, at 6–8 wk of age, the heterozygous Rm155LG transgenic mice[<xref ref-type="bibr" rid="pgen.1006308.ref008">8</xref>] were mated with the homozygous EIIa-Cre transgenic mice (FVB/N-Tg(EIIa-cre)C5379Lmgd/J)[<xref ref-type="bibr" rid="pgen.1006308.ref065">65</xref>] to generate F1 (S1B Fig); next, both luciferase (Luc)- and mRFP-positive F1 animals (2<sup>#</sup>, 4<sup>#</sup> or 6<sup>#</sup>) (shown in S1B-b,c Fig) were intercrossed to produce F2 (shown in S1C Fig), including Luc- and mRFP-positive F2 animals with white fur (6<sup>#</sup>). Finally, both Luc- and mRFP-positive F2 animals with white fur and without Cre gene (determined by PCR-based genotyping) were intercrossed to produce RL-m155 transgenic mice (R: mRFP; L: Luc) (S1D Fig) which can globally and constantly express mRFP (<xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2A Fig</xref>), Luc (<xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2A Fig</xref>) and miR-155 (<xref ref-type="supplementary-material" rid="pgen.1006308.s002">S2B Fig</xref>) transgenes in multiple organs and tissues of RL-m155 transgenic mice. Additionally, the genetic background of RL-m155 mice is FVB/N strain. <bold>(B)</bold> Whole-body fluorescence (b) and bioluminescence (c) imaging for newborn offspring derived from mating <ext-link ext-link-type="uri" xlink:href="http://www.google.com.hk/search?client=pub-0784377849481158&amp;channel=0796295461&amp;forid=&amp;prog=aff&amp;hl=zh-CN&amp;q=heterozygous&amp;spell=1&amp;sa=X" xlink:type="simple">heterozygous</ext-link> Rm155LG transgenic mice with homozygous EIIa-Cre mice. <bold>(C)</bold> In vivo mRFP (b) and luc (c) imaging for newborn offspring derived from intercrossing of both Luc- and mRFP-positive F1 animals (i.e., 2<sup>#</sup>, 4<sup>#</sup> or 6<sup>#</sup>) (shown in S1B-b,c Fig). <bold>(D)</bold> Whole-body fluorescence (b) and bioluminescence (c) imaging for newborn RL-m155 transgenic mice. Both Luc- and mRFP-positive mice (i.e., 4<sup>#</sup>, 5<sup>#</sup> and 6<sup>#</sup>) (shown in S1D Fig) are RL-m155 transgenic mice. <bold>(E)</bold> Whole-body fluorescence (b) and bioluminescence (c) imaging for adult RL-m155 transgenic mice. <bold>(F)</bold> PCR-based genotyping for Cre, mRFP and Luc transgenes in RL-m155 transgenic mice. These RL-m155 transgenic mice (shown in S1D Fig) were individually analyzed by PCR for the genomic integration of Cre, mRFP and Luc transgenes with tail biopsy-derived DNA. PCR products were amplified by the primer pair P1/P2 (specific for mRFP), by the primer pair P3/P4 (specific for Luc) and by the primer pair P5/P6 (specific for Cre), respectively. P1: 5'-GGGAGCGCGTGATGAAC-3', P2: 5'-CGTTGTGGGAGGTGATGTC-3';P3: 5'-AGATACGCCCT GGTTCCTGG-3',P4: 5'-ACGAACACCACGGTAGGCTG-3';P5: 5'-GAACCTGATGGACATGTTC AGG-3', P6:5'-AGTGCGTTCGAACGCTAGAGCCTGT-3'. lane 1: Cre positive control DNA from EIIa-Cre mouse as template; lane 2: positive control (pRm155LG as template); lane 9: negative control using genomic DNA from WT mouse as template. Data are representative of three independent PCR experiments that yield similar results.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Global overexpression of mouse miR-155 transgene in multiple organs and tissues of RL-m155 transgenic mice.</title>
<p><bold>(A)</bold> mRFP and Luc expression in multiple organs and tissues of RL-m155 transgenic mice. The left organ samples in each figure were obtained from one control littermate, while the right organ samples in each figure were isolated from one RL-m155 transgenic mouse. mRFP expression in the postnatal organs and tissues of RL-m155 transgenic mice was assayed under stereo fluorescent microscope (Nikon, AZ100), while bioluminescence imaging for multiple organs and tissues obtained from RL-m155 transgenic mouse and littermate controls was measured noninvasively using the IVIS LuminaIIimaging system (Xenogen Corp., Alameda, CA). Muscle and pancreas from RL-m155R transgenic mice (the right samples in each figure) can be distinguished from their wildtype littermates according to their deep red color under daylight (<xref ref-type="fig" rid="pgen.1006308.g002">Fig 2A</xref>). <bold>(B)</bold> qRT-PCR analysis of the expression of miR-155 transgene in multiple organs and tissues of RL-m155 transgenic mice. BAT: brown adipose tissue; WAT: white adipose tissue. (<bold>C</bold>) RL-m155 (right) and control (left) male littermates at 20 weeks of age. (<bold>D</bold>) RL-m155 (right) and control (left) female littermates at age 12 weeks. <bold>(E-F)</bold> Body weight of control mice vs. RL-m155 transgenic mice at different ages. Values are mean ± SD; n = 5–10 mice per time point. *, <italic>P</italic> &lt; 0.05 compared with control mice;**, <italic>P</italic>&lt;0.01 compared with control mice;#, <italic>P</italic>&lt;0.001 compared with control mice.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>RL-m155 female mice display improved glucose tolerance and enhanced insulin sensitivity.</title>
<p><bold>(A-C)</bold> Blood glucose concentrations in fed-state (A), 12-hour–fasted (B) and 24-hour–fasted (C) mice at indicated ages. <bold>(D)</bold> Serum insulin concentrations in fed-state and 12-hour–fasted mice (5m). <bold>(E-F)</bold> GTT in 12-hour–fasted mice (E) and AUC (F) for this GTT (E). <bold>(G)</bold> Serum insulin measurements performed in 12-hour–fasted mice (3m) during a GTT (E). <bold>(H)</bold> ITT performed on 12-hour–fasted 3-month-old control and RL-m155 mice. <bold>(I)</bold> AUC calculated from mice in (H). <bold>(J)</bold> ITT of 12-hour–fasted control and RL-m155 mice. <bold>(K)</bold> AUC analysis for this ITT (J). Values are statistically significant at *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01 and <sup>#</sup><italic>P</italic>&lt;0.001.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s004" xlink:type="simple">
<label>S4 Fig</label>
<caption>
<title>Glucose metabolism in RL-155 mice fed an HFD.</title>
<p><bold>(A)</bold> Blood glucose concentrations in 24-hour-fasted control (Con) and RL-155 mice (7m) maintained on chow or an HFD (high-fat diet) (60% fat). <bold>(B)</bold> GTT in 12-hour–fasted mice (maintained on chow or an HFD). <bold>(C)</bold> ITT performed on 12-hour–fasted 7-month-old control and RL-m155 mice maintained on chow or an HFD. 28-week-old mice were maintained on chow or were fed an HFD beginning at age 12 wk. For RL-155 mice vs. control mice fed chow: *<italic>P</italic> &lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001; for RL-155 mice vs. control mice fed a high-fat diet: <sup>#</sup><italic>P</italic>&lt;0.05, <sup>##</sup><italic>P</italic>&lt;0.01, <sup>###</sup><italic>P</italic>&lt;0.001.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s005" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s005" xlink:type="simple">
<label>S5 Fig</label>
<caption>
<title>Western blot analysis of PDK4 expression in liver, WAT and skeletal muscle (SM) of RL-m155 mice.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s006" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s006" xlink:type="simple">
<label>S6 Fig</label>
<caption>
<title>Insulin-stimulated Akt phosphorylation in hepa1-6 cells in the absence (miR-con) or presence of miR-155 mimics.</title>
<p>Hepa1-6 cells transfected with miR-155 mimics or mimics control were challenged with human insulin at 50 IU/L or 100 IU/L for 0, 15 and 30min, respectively. Protein levels of total and phosphorylated AKT were detected by Western blotting. The results were obtained from three independent experiments and a representative immunoblot is shown.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s007" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s007" xlink:type="simple">
<label>S7 Fig</label>
<caption>
<title>SOCS1 is a direct target of miR-155.</title>
<p>(<bold>A</bold>) Sequence alignment of 3’-UTR of human (Hsa), mouse (Mmu), rhesus (Mml) and rat (Rno) SOCS1 highlighting miR-155 binding site. (<bold>B</bold>) Sequence alignment of 3’-UTR of human and mouse SOCS1 with respect to miR-155 mature sequence, showing possible interaction through a conserved binding site. (<bold>C</bold>) Immunoblot analysis of SOCS1 expression in liver of RL-m155 transgenic mice and KO mice.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s008" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s008" xlink:type="simple">
<label>S8 Fig</label>
<caption>
<title>qRT-PCR analysis of C/EBPβ, HDAC4 and PDK4 expression in hepa1-6 cells transfected with the indicated siRNA oligonucleotides.</title>
<p>SCR: scrambled siRNA. *, <italic>P</italic> &lt; 0.05 compared with siSCR.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s009" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s009" xlink:type="simple">
<label>S9 Fig</label>
<caption>
<title>(Extended Data <xref ref-type="fig" rid="pgen.1006308.g006">Fig 6F</xref>) The fold changes in <sup>18</sup>F-FDG uptake between miR-155-expressing indicated cells and the corresponding control cells.</title>
<p>Data are presented as fold changes in the miR-155-expressing cells compared to the control cells. UC: untransfected cells. *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; NS, not significant.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s010" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s010" xlink:type="simple">
<label>S10 Fig</label>
<caption>
<title>(Extended Data <xref ref-type="fig" rid="pgen.1006308.g007">Fig 7G</xref>) The fold changes in <sup>18</sup>F-FDG uptake between siRNA-transfected hepa1-6 cells and control cells.</title>
<p>Data are presented as fold changes in siRNA-transfected cells compared to control cells. UC: untransfected cells. *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; NS, not significant.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s011" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s011" xlink:type="simple">
<label>S11 Fig</label>
<caption>
<title>Proposed model for the role of miR-155 in known molecular pathways crucial for improved glucose metabolism.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s012" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s012" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Primers for qRT-PCR analysis of miRNAs.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s013" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s013" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Primers for qRT-PCR analysis of insulin sensitivity-related human genes expression.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s014" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s014" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Primers for qRT-PCR analysis of glucose metabolism and insulin sensitivity-related mouse genes expression.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s015" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s015" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>List of antibodies and suppliers used for immunoblotting and immunohistochemistry.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s016" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s016" xlink:type="simple">
<label>S5 Table</label>
<caption>
<title>The verified or putative miR-155 target genes implicated in insulin signaling, glucose metabolism and diabetes.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s017" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s017" xlink:type="simple">
<label>S1 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g001">Fig 1</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s018" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s018" xlink:type="simple">
<label>S2 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g002">Fig 2</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s019" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s019" xlink:type="simple">
<label>S3 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g003">Fig 3</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s020" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s020" xlink:type="simple">
<label>S4 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g004">Fig 4</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s021" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s021" xlink:type="simple">
<label>S5 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g005">Fig 5</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006308.s022" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006308.s022" xlink:type="simple">
<label>S6 Data</label>
<caption>
<title>Experiment-level data of <xref ref-type="fig" rid="pgen.1006308.g006">Fig 6</xref>.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pgen.1006308.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dumortier</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Hinault</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Van Obberghen</surname> <given-names>E</given-names></name>. <article-title>MicroRNAs and metabolism crosstalk in energy homeostasis</article-title>. <source>Cell metabolism</source>. <year>2013</year>;<volume>18</volume>(<issue>3</issue>):<fpage>312</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2013.06.004" xlink:type="simple">10.1016/j.cmet.2013.06.004</ext-link></comment> <object-id pub-id-type="pmid">23850315</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fernandez-Valverde</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Taft</surname> <given-names>Rj</given-names></name> <name name-style="western"><surname>Mattick</surname> <given-names>JS</given-names></name>. <article-title>MicroRNAs in beta-cell biology, insulin resistance, diabetes and its complications</article-title>. <source>Diabetes</source>. <year>2011</year>;(1939-327X (Electronic)). D—NLM: PMC3121441 EDAT- 2011/06/29 06:00 MHDA- 2011/08/30 06:00 CRDT- 2011/06/29 06:00 AID—60/7/1825 [pii] AID—<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db11-0171" xlink:type="simple">10.2337/db11-0171</ext-link>.</comment> PST—ppublish.</mixed-citation></ref>
<ref id="pgen.1006308.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rottiers</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Naar</surname> <given-names>AM</given-names></name>. <article-title>MicroRNAs in metabolism and metabolic disorders</article-title> <source>Nat Rev Mol Cell Bio</source>. <year>2012</year>;<volume>13</volume>(<issue>5</issue>):<fpage>281-</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/Nrm3328" xlink:type="simple">10.1038/Nrm3328</ext-link>.</comment> WOS:000303111800001.</mixed-citation></ref>
<ref id="pgen.1006308.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ozcan</surname> <given-names>S</given-names></name>. <article-title>Role of microRNAs in diabetes</article-title>. <source>Biochimica et biophysica acta</source>. <year>2008</year>;<volume>1779</volume>(<issue>11</issue>):<fpage>697</fpage>–<lpage>701</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbagrm.2008.06.010" xlink:type="simple">10.1016/j.bbagrm.2008.06.010</ext-link></comment> <object-id pub-id-type="pmid">18655850</object-id>; PubMed Central PMCID: PMC2643014.</mixed-citation></ref>
<ref id="pgen.1006308.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>. <article-title>The pivotal role of microRNA-155 in the control of cancer</article-title>. <source>Journal of cellular physiology</source>. <year>2014</year>;<volume>229</volume>(<issue>5</issue>):<fpage>545</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcp.24492" xlink:type="simple">10.1002/jcp.24492</ext-link></comment> <object-id pub-id-type="pmid">24122356</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elton</surname> <given-names>TS</given-names></name>, <name name-style="western"><surname>Selemon</surname> <given-names>H</given-names></name> <name name-style="western"><surname>Elton</surname> <given-names>Sm</given-names></name> <name name-style="western"><surname>Parinandi</surname> <given-names>NL</given-names></name>. <article-title>Regulation of the MIR155 host gene in physiological and pathological processes</article-title>. <source>Gene</source>. <year>2013</year>;(1879–0038 (Electronic)).</mixed-citation></ref>
<ref id="pgen.1006308.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faraoni</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Antonetti</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Cardone</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bonmassar</surname> <given-names>E</given-names></name>. <article-title>miR-155 gene: a typical multifunctional microRNA</article-title>. <source>Biochimica et biophysica acta</source>. <year>2009</year>;<volume>1792</volume>(<issue>6</issue>):<fpage>497</fpage>–<lpage>505</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbadis.2009.02.013" xlink:type="simple">10.1016/j.bbadis.2009.02.013</ext-link></comment> <object-id pub-id-type="pmid">19268705</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0118417</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0118417" xlink:type="simple">10.1371/journal.pone.0118417</ext-link></comment> <object-id pub-id-type="pmid">25799309</object-id>; PubMed Central PMCID: PMC4370457.</mixed-citation></ref>
<ref id="pgen.1006308.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baldeon</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Weigelt</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>de Wit</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ozcan</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>van Oudenaren</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sempertegui</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Decreased Serum Level of miR-146a as Sign of Chronic Inflammation in Type 2 Diabetic Patients</article-title>. <source>PloS one</source>. <year>2014</year>;<volume>9</volume>(<issue>12</issue>). ARTN <fpage>e115209</fpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0115209" xlink:type="simple">10.1371/journal.pone.0115209</ext-link>.</comment> WOS:000346375400083. <object-id pub-id-type="pmid">25500583</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Balasubramanyam</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aravind</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gokulakrishnan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Prabu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sathishkumar</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ranjani</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes</article-title>. <source>Mol Cell Biochem</source>. <year>2011</year>;<volume>351</volume>(<issue>1–2</issue>):<fpage>197</fpage>–<lpage>205</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11010-011-0727-3" xlink:type="simple">10.1007/s11010-011-0727-3</ext-link>.</comment> WOS:000288963800022. <object-id pub-id-type="pmid">21249428</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Corral-Fernandez</surname> <given-names>NE</given-names></name>, <name name-style="western"><surname>Salgado-Bustamante</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Martinez-Leija</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Cortez-Espinosa</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Garcia-Hernandez</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Reynaga-Hernandez</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Dysregulated miR-155 Expression in Peripheral Blood Mononuclear Cells from Patients with Type 2 Diabetes</article-title>. <source>Exp Clin Endocr Diab</source>. <year>2013</year>;<volume>121</volume>(<issue>6</issue>):<fpage>347</fpage>–<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-0033-1341516" xlink:type="simple">10.1055/s-0033-1341516</ext-link>.</comment> WOS:000320100200006.</mixed-citation></ref>
<ref id="pgen.1006308.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trajkovski</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hausser</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Soutschek</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bhat</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Akin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zavolan</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>MicroRNAs 103 and 107 regulate insulin sensitivity</article-title>. <source>Nature</source>. <year>2011</year>;<volume>474</volume>(<issue>7353</issue>):<fpage>649</fpage>–<lpage>U127</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/Nature10112" xlink:type="simple">10.1038/Nature10112</ext-link>.</comment> WOS:000292204300041. <object-id pub-id-type="pmid">21654750</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thai</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Calado</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Casola</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ansel</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Xue</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Regulation of the germinal center response by microRNA-155</article-title>. <source>Science</source>. <year>2007</year>;<volume>316</volume>(<issue>5824</issue>):<fpage>604</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1141229" xlink:type="simple">10.1126/science.1141229</ext-link></comment> <object-id pub-id-type="pmid">17463289</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Liao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect</article-title>. <source>Oncogene</source>. <year>2015</year>;<volume>34</volume>(<issue>21</issue>):<fpage>2700</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/onc.2014.204" xlink:type="simple">10.1038/onc.2014.204</ext-link></comment> <object-id pub-id-type="pmid">25043301</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoshizawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hinoi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Jung</surname> <given-names>DY</given-names></name>, <name name-style="western"><surname>Kajimura</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ferron</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts</article-title>. <source>The Journal of clinical investigation</source>. <year>2009</year>;<volume>119</volume>(<issue>9</issue>):<fpage>2807</fpage>–<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI39366" xlink:type="simple">10.1172/JCI39366</ext-link>.</comment> PMC2735903. <object-id pub-id-type="pmid">19726872</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Shao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Muhlenkamp</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Klepcyk</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein beta</article-title>. <source>The Journal of biological chemistry</source>. <year>2000</year>;<volume>275</volume>(<issue>19</issue>):<fpage>14173</fpage>–<lpage>81</lpage>. <object-id pub-id-type="pmid">10747954</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luan</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Goodarzi</surname> <given-names>MO</given-names></name>, <name name-style="western"><surname>Phillips</surname> <given-names>NG</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YD</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4</article-title>. <source>Cell metabolism</source>. <year>2014</year>;<volume>19</volume>(<issue>6</issue>):<fpage>1058</fpage>–<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2014.03.024" xlink:type="simple">10.1016/j.cmet.2014.03.024</ext-link></comment> <object-id pub-id-type="pmid">24768298</object-id>; PubMed Central PMCID: PMC4207085.</mixed-citation></ref>
<ref id="pgen.1006308.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mitchell</surname> <given-names>F</given-names></name>. <article-title>Diabetes: PTEN mutations increase insulin sensitivity and obesity</article-title>. <source>Nature reviews Endocrinology</source>. <year>2012</year>;<volume>8</volume>(<issue>12</issue>):<fpage>698</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrendo.2012.186" xlink:type="simple">10.1038/nrendo.2012.186</ext-link></comment> <object-id pub-id-type="pmid">23032179</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Howard</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Flier</surname> <given-names>JS</given-names></name>. <article-title>Attenuation of leptin and insulin signaling by SOCS proteins</article-title>. <source>Trends in endocrinology and metabolism: TEM</source>. <year>2006</year>;<volume>17</volume>(<issue>9</issue>):<fpage>365</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tem.2006.09.007" xlink:type="simple">10.1016/j.tem.2006.09.007</ext-link></comment> <object-id pub-id-type="pmid">17010638</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ueki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tseng</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Kahn</surname> <given-names>CR</given-names></name>. <article-title>Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2004</year>;<volume>101</volume>(<issue>28</issue>):<fpage>10422</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0402511101" xlink:type="simple">10.1073/pnas.0402511101</ext-link></comment> <object-id pub-id-type="pmid">15240880</object-id>; PubMed Central PMCID: PMC478587.</mixed-citation></ref>
<ref id="pgen.1006308.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taniguchi</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Emanuelli</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kahn</surname> <given-names>CR</given-names></name>. <article-title>Critical nodes in signalling pathways: insights into insulin action</article-title>. <source>Nat Rev Mol Cell Bio</source>. <year>2006</year>;<volume>7</volume>(<issue>2</issue>):<fpage>85</fpage>–<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/Nrm1837" xlink:type="simple">10.1038/Nrm1837</ext-link>.</comment> WOS:000235590100012.</mixed-citation></ref>
<ref id="pgen.1006308.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Croniger</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Arizmendi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Harada-Shiba</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Poli</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene</article-title>. <source>The Journal of clinical investigation</source>. <year>1999</year>;<volume>103</volume>(<issue>2</issue>):<fpage>207</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI4243" xlink:type="simple">10.1172/JCI4243</ext-link></comment> <object-id pub-id-type="pmid">9916132</object-id>; PubMed Central PMCID: PMC407878.</mixed-citation></ref>
<ref id="pgen.1006308.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mihaylova</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Vasquez</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Ravnskjaer</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Denechaud</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>RT</given-names></name>, <name name-style="western"><surname>Alvarez</surname> <given-names>JG</given-names></name>, <etal>et al</etal>. <article-title>Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis</article-title>. <source>Cell</source>. <year>2011</year>;<volume>145</volume>(<issue>4</issue>):<fpage>607</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2011.03.043" xlink:type="simple">10.1016/j.cell.2011.03.043</ext-link></comment> <object-id pub-id-type="pmid">21565617</object-id>; PubMed Central PMCID: PMC3117637.</mixed-citation></ref>
<ref id="pgen.1006308.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ye</surname> <given-names>J</given-names></name>. <article-title>Improving insulin sensitivity with HDAC inhibitor</article-title>. <source>Diabetes</source>. <year>2013</year>;<volume>62</volume>(<issue>3</issue>):<fpage>685</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db12-1354" xlink:type="simple">10.2337/db12-1354</ext-link></comment> <object-id pub-id-type="pmid">23431009</object-id>; PubMed Central PMCID: PMC3581218.</mixed-citation></ref>
<ref id="pgen.1006308.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Galic</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sachithanandan</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kay</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Steinberg</surname> <given-names>GR</given-names></name>. <article-title>Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity</article-title>. <source>Biochem J</source>. <year>2014</year>;<volume>461</volume>:<fpage>177</fpage>–<lpage>88</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/Bj20140143" xlink:type="simple">10.1042/Bj20140143</ext-link>.</comment> WOS:000338489400002. <object-id pub-id-type="pmid">24966052</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rui</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yuan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Frantz</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Shoelson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>MF</given-names></name>. <article-title>SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2</article-title>. <source>The Journal of biological chemistry</source>. <year>2002</year>;<volume>277</volume>(<issue>44</issue>):<fpage>42394</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.C200444200" xlink:type="simple">10.1074/jbc.C200444200</ext-link></comment> <object-id pub-id-type="pmid">12228220</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wada</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hoshino</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kimura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ojima</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nakano</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Koya</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes</article-title>. <source>Am J Physiol-Endoc M</source>. <year>2011</year>;<volume>300</volume>(<issue>6</issue>):<fpage>E1112</fpage>–<lpage>E23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpendo.00370.2010" xlink:type="simple">10.1152/ajpendo.00370.2010</ext-link>.</comment> WOS:000290959000019.</mixed-citation></ref>
<ref id="pgen.1006308.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jiang</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>XH</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>(<issue>8</issue>):<fpage>3119</fpage>–<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.Can-09-4250" xlink:type="simple">10.1158/0008-5472.Can-09-4250</ext-link>.</comment> WOS:000278486100016. <object-id pub-id-type="pmid">20354188</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lu</surname> <given-names>LF</given-names></name>, <name name-style="western"><surname>Thai</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Calado</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Chaudhry</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kubo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein</article-title>. <source>Immunity</source>. <year>2009</year>;<volume>30</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.immuni.2008.11.010" xlink:type="simple">10.1016/j.immuni.2008.11.010</ext-link>.</comment> WOS:000262769900012. <object-id pub-id-type="pmid">19144316</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>XG</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Inducible microRNA-155 Feedback Promotes Type I IFN Signaling in Antiviral Innate Immunity by Targeting Suppressor of Cytokine Signaling 1</article-title>. <source>J Immunol</source>. <year>2010</year>;<volume>185</volume>(<issue>10</issue>):<fpage>6226</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.1000491" xlink:type="simple">10.4049/jimmunol.1000491</ext-link>.</comment> WOS:000283848000061. <object-id pub-id-type="pmid">20937844</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rome</surname> <given-names>S</given-names></name>. <article-title>Are extracellular microRNAs involved in type 2 diabetes and related pathologies?</article-title> <source>Clinical biochemistry</source>. <year>2013</year>;<volume>46</volume>(<issue>10–11</issue>):<fpage>937</fpage>–<lpage>45</lpage>. Epub 2013/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinbiochem.2013.02.018" xlink:type="simple">10.1016/j.clinbiochem.2013.02.018</ext-link></comment> <object-id pub-id-type="pmid">23499584</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fichtlscherer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>De Rosa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fox</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Schwietz</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Fischer</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Liebetrau</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Circulating microRNAs in patients with coronary artery disease</article-title>. <source>Circulation research</source>. <year>2010</year>;<volume>107</volume>(<issue>5</issue>):<fpage>677</fpage>–<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.109.215566" xlink:type="simple">10.1161/CIRCRESAHA.109.215566</ext-link></comment> <object-id pub-id-type="pmid">20595655</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khamaneh</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Alipour</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Sheikhzadeh Hesari</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ghadiri Soufi</surname> <given-names>F</given-names></name>. <article-title>A signature of microRNA-155 in the pathogenesis of diabetic complications</article-title>. <source>Journal of physiology and biochemistry</source>. <year>2015</year>;<volume>71</volume>(<issue>2</issue>):<fpage>301</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s13105-015-0413-0" xlink:type="simple">10.1007/s13105-015-0413-0</ext-link></comment> <object-id pub-id-type="pmid">25929727</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mitchell</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Parkin</surname> <given-names>RK</given-names></name>, <name name-style="western"><surname>Kroh</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Fritz</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Wyman</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Pogosova-Agadjanyan</surname> <given-names>EL</given-names></name>, <etal>et al</etal>. <article-title>Circulating microRNAs as stable blood-based markers for cancer detection</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2008</year>;<volume>105</volume>(<issue>30</issue>):<fpage>10513</fpage>–<lpage>8</lpage>. Epub 2008/07/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0804549105" xlink:type="simple">10.1073/pnas.0804549105</ext-link></comment> <object-id pub-id-type="pmid">18663219</object-id>; PubMed Central PMCID: PMCPmc2492472.</mixed-citation></ref>
<ref id="pgen.1006308.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adachi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nakanishi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Otsuka</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nishimura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hirokawa</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Goto</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Plasma microRNA 499 as a biomarker of acute myocardial infarction</article-title>. <source>Clinical chemistry</source>. <year>2010</year>;<volume>56</volume>(<issue>7</issue>):<fpage>1183</fpage>–<lpage>5</lpage>. Epub 2010/04/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1373/clinchem.2010.144121" xlink:type="simple">10.1373/clinchem.2010.144121</ext-link></comment> <object-id pub-id-type="pmid">20395621</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ai</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Pu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Jiao</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction</article-title>. <source>Biochemical and biophysical research communications</source>. <year>2010</year>;<volume>391</volume>(<issue>1</issue>):<fpage>73</fpage>–<lpage>7</lpage>. Epub 2009/11/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2009.11.005" xlink:type="simple">10.1016/j.bbrc.2009.11.005</ext-link></comment> <object-id pub-id-type="pmid">19896465</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bostjancic</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Zidar</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Stajer</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Glavac</surname> <given-names>D</given-names></name>. <article-title>MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction</article-title>. <source>Cardiology</source>. <year>2010</year>;<volume>115</volume>(<issue>3</issue>):<fpage>163</fpage>–<lpage>9</lpage>. Epub 2009/12/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000268088" xlink:type="simple">10.1159/000268088</ext-link></comment> <object-id pub-id-type="pmid">20029200</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ji</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hiura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hirokawa</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Fukushima</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Iwai</surname> <given-names>N</given-names></name>. <article-title>Plasma miR-208 as a biomarker of myocardial injury</article-title>. <source>Clinical chemistry</source>. <year>2009</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1944</fpage>–<lpage>9</lpage>. Epub 2009/08/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1373/clinchem.2009.125310" xlink:type="simple">10.1373/clinchem.2009.125310</ext-link></comment> <object-id pub-id-type="pmid">19696117</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>GK</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>JQ</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans</article-title>. <source>European heart journal</source>. <year>2010</year>;<volume>31</volume>(<issue>6</issue>):<fpage>659</fpage>–<lpage>66</lpage>. Epub 2010/02/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehq013" xlink:type="simple">10.1093/eurheartj/ehq013</ext-link></comment> <object-id pub-id-type="pmid">20159880</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karolina</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Armugam</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tavintharan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Sum</surname> <given-names>CF</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus</article-title>. <source>PloS one</source>. <year>2011</year>;<volume>6</volume>(<issue>8</issue>):<fpage>e22839</fpage>. Epub 2011/08/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0022839" xlink:type="simple">10.1371/journal.pone.0022839</ext-link></comment> <object-id pub-id-type="pmid">21829658</object-id>; PubMed Central PMCID: PMCPmc3148231.</mixed-citation></ref>
<ref id="pgen.1006308.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiao</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>8</issue>):<fpage>2631</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db13-1689" xlink:type="simple">10.2337/db13-1689</ext-link></comment> <object-id pub-id-type="pmid">24677715</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Tian</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lefebvre</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids</article-title>. <source>The Journal of clinical investigation</source>. <year>2015</year>;<volume>125</volume>(<issue>6</issue>):<fpage>2497</fpage>–<lpage>509</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI75438" xlink:type="simple">10.1172/JCI75438</ext-link></comment> <object-id pub-id-type="pmid">25961460</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Attia</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Janssen</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Friedman</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Regulation of Pyruvate Dehydrogenase Kinase 4 (PDK4) by CCAAT/Enhancer-binding Protein beta (C/EBP beta)</article-title>. <source>Journal of Biological Chemistry</source>. <year>2011</year>;<volume>286</volume>(<issue>27</issue>):<fpage>23799</fpage>–<lpage>807</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M111.246389" xlink:type="simple">10.1074/jbc.M111.246389</ext-link>.</comment> WOS:000292294900022. <object-id pub-id-type="pmid">21586575</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jeong</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Jeoung</surname> <given-names>NH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>KG</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>IK</given-names></name>. <article-title>Transcriptional regulation of pyruvate dehydrogenase kinase</article-title>. <source>Diabetes &amp; metabolism journal</source>. <year>2012</year>;<volume>36</volume>(<issue>5</issue>):<fpage>328</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4093/dmj.2012.36.5.328" xlink:type="simple">10.4093/dmj.2012.36.5.328</ext-link></comment> <object-id pub-id-type="pmid">23130316</object-id>; PubMed Central PMCID: PMC3486978.</mixed-citation></ref>
<ref id="pgen.1006308.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jeoung</surname> <given-names>NH</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>RA</given-names></name>. <article-title>Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice</article-title>. <source>American journal of physiology Endocrinology and metabolism</source>. <year>2008</year>;<volume>295</volume>(<issue>1</issue>):<fpage>E46</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpendo.00536.2007" xlink:type="simple">10.1152/ajpendo.00536.2007</ext-link></comment> <object-id pub-id-type="pmid">18430968</object-id>; PubMed Central PMCID: PMC2493588.</mixed-citation></ref>
<ref id="pgen.1006308.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jeoung</surname> <given-names>NH</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>RA</given-names></name>. <article-title>Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels</article-title>. <source>Korean diabetes journal</source>. <year>2010</year>;<volume>34</volume>(<issue>5</issue>):<fpage>274</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4093/kdj.2010.34.5.274" xlink:type="simple">10.4093/kdj.2010.34.5.274</ext-link></comment> <object-id pub-id-type="pmid">21076574</object-id>; PubMed Central PMCID: PMC2972486.</mixed-citation></ref>
<ref id="pgen.1006308.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weems</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Griesel</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>AL</given-names></name>. <article-title>Class II Histone Deacetylases Downregulate GLUT4 Transcription in Response to Increased cAMP Signaling in Cultured Adipocytes and Fasting Mice</article-title>. <source>Diabetes</source>. <year>2012</year>;<volume>61</volume>(<issue>6</issue>):<fpage>1404</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/Db11-0737" xlink:type="simple">10.2337/Db11-0737</ext-link>.</comment> WOS:000304490100017. <object-id pub-id-type="pmid">22403301</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henriksson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sall</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gormand</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wasserstrom</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Morrice</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Fritzen</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes</article-title>. <source>J Cell Sci</source>. <year>2015</year>;<volume>128</volume>(<issue>3</issue>):<fpage>472</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/Jcs.153932" xlink:type="simple">10.1242/Jcs.153932</ext-link>.</comment> WOS:000349017900006. <object-id pub-id-type="pmid">25472719</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Siegel</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kipschull</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Haas</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Frohlich</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Meister</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit</article-title>. <source>Nature communications</source>. <year>2013</year>;<volume>4</volume>:<fpage>1769</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms2742" xlink:type="simple">10.1038/ncomms2742</ext-link></comment> <object-id pub-id-type="pmid">23612310</object-id>; PubMed Central PMCID: PMC3644088.</mixed-citation></ref>
<ref id="pgen.1006308.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>J</given-names></name>. <article-title>TNFalpha-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors</article-title>. <source>Biochemical and biophysical research communications</source>. <year>2011</year>;<volume>414</volume>(<issue>3</issue>):<fpage>618</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2011.09.131" xlink:type="simple">10.1016/j.bbrc.2011.09.131</ext-link></comment> <object-id pub-id-type="pmid">21986534</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Skarn</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Namlos</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Noordhuis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>MY</given-names></name>, <name name-style="western"><surname>Meza-Zepeda</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Myklebost</surname> <given-names>O</given-names></name>. <article-title>Adipocyte Differentiation of Human Bone Marrow-Derived Stromal Cells Is Modulated by MicroRNA-155, MicroRNA-221, and MicroRNA-222</article-title>. <source>Stem Cells Dev</source>. <year>2012</year>;<volume>21</volume>(<issue>6</issue>):<fpage>873</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/scd.2010.0503" xlink:type="simple">10.1089/scd.2010.0503</ext-link>.</comment> WOS:000302222700006. <object-id pub-id-type="pmid">21756067</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miller</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Gilchrist</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Nijjar</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Araldi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ramirez</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Lavery</surname> <given-names>CA</given-names></name>, <etal>et al</etal>. <article-title>MiR-155 Has a Protective Role in the Development of Non-Alcoholic Hepatosteatosis in Mice</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>8</issue>). ARTN <fpage>e72324</fpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0072324" xlink:type="simple">10.1371/journal.pone.0072324</ext-link>.</comment> WOS:000324470100098. <object-id pub-id-type="pmid">23991091</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hu</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kagele</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Huffaker</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Runtsch</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation</article-title>. <source>Immunity</source>. <year>2014</year>;<volume>41</volume>(<issue>4</issue>):<fpage>605</fpage>–<lpage>19</lpage>. Epub 2014/11/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.immuni.2014.09.015" xlink:type="simple">10.1016/j.immuni.2014.09.015</ext-link></comment> <object-id pub-id-type="pmid">25367574</object-id>; PubMed Central PMCID: PMCPmc4657560.</mixed-citation></ref>
<ref id="pgen.1006308.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Badeanlou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Furlan-Freguia</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ruf</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Samad</surname> <given-names>F</given-names></name>. <article-title>Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation</article-title>. <source>Nature medicine</source>. <year>2011</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1490</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.2461" xlink:type="simple">10.1038/nm.2461</ext-link></comment> <object-id pub-id-type="pmid">22019885</object-id>; PubMed Central PMCID: PMC3210891.</mixed-citation></ref>
<ref id="pgen.1006308.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>HV</given-names></name>, <name name-style="western"><surname>Accili</surname> <given-names>D</given-names></name>. <article-title>Hormonal regulation of hepatic glucose production in health and disease</article-title>. <source>Cell metabolism</source>. <year>2011</year>;<volume>14</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>19</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2011.06.003" xlink:type="simple">10.1016/j.cmet.2011.06.003</ext-link></comment> <object-id pub-id-type="pmid">21723500</object-id>; PubMed Central PMCID: PMC3131084.</mixed-citation></ref>
<ref id="pgen.1006308.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alberti</surname> <given-names>KG</given-names></name>, <name name-style="western"><surname>Zimmet</surname> <given-names>PZ</given-names></name>. <article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation</article-title>. <source>Diabetic medicine: a journal of the British Diabetic Association</source>. <year>1998</year>;<volume>15</volume>(<issue>7</issue>):<fpage>539</fpage>–<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1096-9136(199807)15:7&lt;539::AID-DIA668&gt;3.0.CO;2-S" xlink:type="simple">10.1002/(SICI)1096-9136(199807)15:7&lt;539::AID-DIA668&gt;3.0.CO;2-S</ext-link></comment> <object-id pub-id-type="pmid">9686693</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matthews</surname> <given-names>Dr</given-names></name> <name name-style="western"><surname>Hosker</surname> <given-names>Jp</given-names></name> <name name-style="western"><surname>Rudenski</surname> <given-names>As</given-names></name> <name name-style="western"><surname>Naylor</surname> <given-names>Ba</given-names></name> <name name-style="western"><surname>Treacher</surname> <given-names>Df</given-names></name> <name name-style="western"><surname>Turner</surname> <given-names>RC</given-names></name>. <article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title>. <source>Diabetologia</source>. <year>1985</year>;<volume>28</volume>(0012-186X (Print)):<fpage>412</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">3899825</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Du</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>XL</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>RY</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Generation of Rm21LG transgenic mice: a powerful tool to generate conditional overexpression of miR-21 that is involved in oncogenesis</article-title>. <source>Biotechnol Lett</source>. <year>2014</year>;<volume>36</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10529-013-1327-y" xlink:type="simple">10.1007/s10529-013-1327-y</ext-link>.</comment> WOS:000329228800002. <object-id pub-id-type="pmid">24068500</object-id></mixed-citation></ref>
<ref id="pgen.1006308.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Simple and rapid determination of homozygous transgenic mice via in vivo fluorescence imaging</article-title>. <source>Oncotarget</source>. <year>2015</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.18632/oncotarget.5535" xlink:type="simple">10.18632/oncotarget.5535</ext-link></comment> <object-id pub-id-type="pmid">26472024</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gao</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>YQ</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>YQ</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>JQ</given-names></name>, <etal>et al</etal>. <article-title>Hes1 is involved in the self-renewal and tumourigenicity of stem-like cancer cells in colon cancer</article-title>. <source>Sci Rep-Uk</source>. <year>2014</year>;<volume>4</volume>. Artn <fpage>3963</fpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/Srep03963" xlink:type="simple">10.1038/Srep03963</ext-link>.</comment> WOS:000331217600004.</mixed-citation></ref>
<ref id="pgen.1006308.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>XL</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Hes1 triggers epithelial-mesenchymal transition (EMT)-like cellular marker alterations and promotes invasion and metastasis of nasopharyngeal carcinoma by activating the PTEN/AKT pathway</article-title>. <source>Oncotarget</source>. <year>2015</year>;<volume>6</volume>(<issue>34</issue>):<fpage>36713</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.18632/oncotarget.5457" xlink:type="simple">10.18632/oncotarget.5457</ext-link></comment> <object-id pub-id-type="pmid">26452025</object-id>; PubMed Central PMCID: PMC4742206.</mixed-citation></ref>
<ref id="pgen.1006308.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xie</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Targeted Disruption of miR-17-92 Impairs Mouse Spermatogenesis by Activating mTOR Signaling Pathway</article-title>. <source>Medicine</source>. <year>2016</year>;<volume>95</volume>(<issue>7</issue>):<fpage>e2713</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MD.0000000000002713" xlink:type="simple">10.1097/MD.0000000000002713</ext-link></comment> <object-id pub-id-type="pmid">26886608</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>XL</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>JW</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA</article-title>. <source>PloS one</source>. <year>2014</year>;<volume>9</volume>(<issue>7</issue>):<fpage>e101330</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0101330" xlink:type="simple">10.1371/journal.pone.0101330</ext-link></comment> <object-id pub-id-type="pmid">24992599</object-id>; PubMed Central PMCID: PMC4081555.</mixed-citation></ref>
<ref id="pgen.1006308.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>XL</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition</article-title>. <source>Laboratory investigation; a journal of technical methods and pathology</source>. <year>2015</year>;<volume>95</volume>(<issue>9</issue>):<fpage>1056</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/labinvest.2015.76" xlink:type="simple">10.1038/labinvest.2015.76</ext-link></comment> <object-id pub-id-type="pmid">26098000</object-id>.</mixed-citation></ref>
<ref id="pgen.1006308.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lakso</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pichel</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Gorman</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Sauer</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Okamoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Efficient in vivo manipulation of mouse genomic sequences at the zygote stage</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>1996</year>;<volume>93</volume>(<issue>12</issue>):<fpage>5860</fpage>–<lpage>5</lpage>. PMC39152. <object-id pub-id-type="pmid">8650183</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>